Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Lung Cancer

  Free Subscription


Articles published in J Thorac Oncol

Retrieve available abstracts of 543 articles:
HTML format



Single Articles


    January 2022
  1. SHILPAKAR R, Paudel BD, Sharma R, Silwal SR, et al
    Lung Cancer in Nepal.
    J Thorac Oncol. 2022;17:22-29.
    PubMed    


  2. MASAGO K, Fujita S
    Effect of Coronavirus Disease 2019 Vaccine-Related Lymphadenopathy on Lung Cancer Treatment.
    J Thorac Oncol. 2022;17:16-18.
    PubMed    


  3. SALLOUM RG, Braithwaite D
    Expansion of Guideline-Recommended Lung Cancer Screening Eligibility: Implications for Health Equity of Joint Screening and Cessation Interventions.
    J Thorac Oncol. 2022;17:13-15.
    PubMed    


    December 2021
  4. CHO BC, Han JY, Kim SW, Lee KH, et al
    A Phase 1/2 Study of Lazertinib 240 mg in Patients with Advanced EGFR T790M-Positive Non-Small Cell Lung Cancer After Prior EGFR Tyrosine Kinase Inhibitors.
    J Thorac Oncol. 2021 Dec 24. pii: S1556-0864(21)03403.
    PubMed     Abstract available


  5. CAINI S, Del Riccio M, Vettori V, Scotti V, et al
    Quitting smoking at or around diagnosis improves the overall survival of lung cancer patients: a systematic review and meta-analysis.
    J Thorac Oncol. 2021 Dec 17. pii: S1556-0864(21)03404.
    PubMed     Abstract available


  6. REN S, Chen J, Xu X, Jiang T, et al
    Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous non-small-cell lung cancer (CameL-sq): a phase 3 trial.
    J Thorac Oncol. 2021 Dec 16. pii: S1556-0864(21)03392.
    PubMed     Abstract available


  7. EBERL M, Tanaka LF, Kraywinkel K, Klug SJ, et al
    Incidence of smoking-related second primary cancers after lung cancer in Germany: an analysis of nationwide cancer registry data.
    J Thorac Oncol. 2021 Dec 10. pii: S1556-0864(21)03390.
    PubMed     Abstract available


  8. HUBER RM, Cavic M, Kerpel-Fronius A, Viola L, et al
    Lung Cancer Screening Considerations During Respiratory Infection Outbreaks, Epidemics or Pandemics: An IASLC Early Detection and Screening Committee Report.
    J Thorac Oncol. 2021 Dec 2. pii: S1556-0864(21)03326.
    PubMed     Abstract available


  9. PARK S, Choi CM, Hwang SS, Choi YL, et al
    Lung Cancer in Korea.
    J Thorac Oncol. 2021;16:1988-1993.
    PubMed    


  10. BIAN Y, Liang J, Shan G, Zhan C, et al
    Combining Clinical and Molecular Characteristics to Precisely Predict the Prognosis of Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2021;16:e99-e100.
    PubMed    


  11. KUMAR A, Kumar S, Gilja S, Potter A, et al
    Encouraging Guideline-Concordant Treatment for T3 NSCLC.
    J Thorac Oncol. 2021;16:e98-e99.
    PubMed    


  12. LI M, Liang J, Bi G, Zhan C, et al
    Could T3Satell Tumors Be Considered Reclassified as T2b?
    J Thorac Oncol. 2021;16:e97-e98.
    PubMed    


  13. MORGENSZTERN D, Govindan R
    Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation.
    J Thorac Oncol. 2021;16:1999-2001.
    PubMed    


  14. AREDO JV, Hellyer JA, Neal JW, Wakelee HA, et al
    Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:1994-1998.
    PubMed    


  15. BELDA-SANCHIS J, Trujillo-Reyes JC, Martinez-Tellez E, Cladellas-Gutierrez E, et al
    Brain Metastasis From Thymic Epithelial Tumors: Strengthening the Evidence, a Call for Action.
    J Thorac Oncol. 2021;16:1984-1987.
    PubMed    


  16. PELOSI G
    KEAP1 and TP53 (Co)mutation in Lung Adenocarcinoma: Another Bullet for Immunotherapy?
    J Thorac Oncol. 2021;16:1979-1983.
    PubMed    


  17. BUGLIONI S, Marino M
    Pitfalls in Molecular Testing and the Added Value of the Cancer Research Biomedical Community.
    J Thorac Oncol. 2021;16:1976-1978.
    PubMed    


  18. BENITEZ JC, Boucher ME, Dansin E, Kerjouan M, et al
    Central Nervous System Metastases in Thymic Epithelial Tumors: A Brief Report of Real-World Insight From RYTHMIC.
    J Thorac Oncol. 2021;16:2144-2149.
    PubMed     Abstract available


  19. SCALERA S, Mazzotta M, Corleone G, Sperati F, et al
    KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy.
    J Thorac Oncol. 2021;16:2065-2077.
    PubMed     Abstract available


  20. TEISHIKATA T, Shiraishi K, Shinno Y, Kobayashi Y, et al
    An Alert to Possible False Positives With a Commercial Assay for MET Exon 14 Skipping.
    J Thorac Oncol. 2021;16:2133-2138.
    PubMed     Abstract available


  21. YANG Y, Sun J, Wang Z, Fang J, et al
    Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study.
    J Thorac Oncol. 2021;16:2109-2120.
    PubMed     Abstract available


    November 2021
  22. LEIGHL NB, Laurie SA, Goss GD, Hughes BGM, et al
    CCTG BR34: A randomized phase II trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic non-small cell lung cancer.
    J Thorac Oncol. 2021 Nov 17. pii: S1556-0864(21)03322.
    PubMed     Abstract available


  23. ROLFO C, Meshulami N, Russo A, Krammer F, et al
    Lung Cancer and SARS-CoV-2 infection: Identifying important knowledge gaps for investigation.
    J Thorac Oncol. 2021 Nov 10. pii: S1556-0864(21)03309.
    PubMed     Abstract available


  24. STOCK-MARTINEAU S, Shepherd FA
    EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:1793-1797.
    PubMed    


  25. MOORE S, Wheatley-Price P
    EGFR Combination Therapy Should Become the New Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:1788-1792.
    PubMed    


  26. YANG C, Li Y, Xiao SY
    Do We Really Understand the Relationship Between Expression of ACE2 and Coronavirus Disease 2019 Lung Pathophysiology?
    J Thorac Oncol. 2021;16:1785-1787.
    PubMed    


  27. LOPEZ-CASTRO R, Recondo G, Gorria T, Mezquita L, et al
    A New Pretreatment Mesothelioma Risk Score: Integrating Clinical and Molecular Factors for Predicting Outcomes in Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2021;16:1782-1784.
    PubMed    


  28. ZHU VW, Ou SI
    Ensartinib (X-396), an Approved ALK Inhibitor, Falls Out as a Clinically Relevant ROS1 Inhibitor.
    J Thorac Oncol. 2021;16:1778-1781.
    PubMed    


  29. ADJEI AA
    Tackling the High Cost of Oncology Drugs.
    J Thorac Oncol. 2021;16:1774-1777.
    PubMed    


  30. DE BAERE T, Woodrum D, Tselikas L, Abtin F, et al
    The ECLIPSE Study: Efficacy of Cryoablation on Metastatic Lung Tumors With a 5-Year Follow-Up.
    J Thorac Oncol. 2021;16:1840-1849.
    PubMed     Abstract available


  31. MIKUBO M, Inoue Y, Liu G, Tsao MS, et al
    Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy.
    J Thorac Oncol. 2021;16:1798-1809.
    PubMed     Abstract available


  32. VAN DEN BROEK MFM, Levy S, Buikhuisen WA, Dijke K, et al
    Well-Differentiated Bronchopulmonary Neuroendocrine Tumors: More Than One Entity.
    J Thorac Oncol. 2021;16:1810-1820.
    PubMed     Abstract available


  33. CHIAPPETTA M, Lococo F, Zanfrini E, Moroni R, et al
    The International Thymic Malignancy Interest Group Classification of Thymoma Recurrence: Survival Analysis and Perspectives.
    J Thorac Oncol. 2021;16:1936-1945.
    PubMed     Abstract available


  34. SAALFELD FC, Wenzel C, Christopoulos P, Merkelbach-Bruse S, et al
    Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations.
    J Thorac Oncol. 2021;16:1952-1958.
    PubMed     Abstract available


  35. YEAP BY, De Rienzo A, Gill RR, Oster ME, et al
    Mesothelioma Risk Score: A New Prognostic Pretreatment, Clinical-Molecular Algorithm for Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2021;16:1925-1935.
    PubMed     Abstract available


    October 2021
  36. PAZ-ARES LG, Ramalingam SS, Ciuleanu TE, Lee JS, et al
    First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
    J Thorac Oncol. 2021 Oct 11. pii: S1556-0864(21)03207.
    PubMed     Abstract available


  37. MEZA R, Cao P, Jeon J, Taylor KL, et al
    Brief Report: Impact of joint lung cancer screening and cessation interventions under the new USPSTF recommendations.
    J Thorac Oncol. 2021 Oct 11. pii: S1556-0864(21)03208.
    PubMed     Abstract available


  38. ROBBINS HA, Cheung LC, Chaturvedi AK, Baldwin DR, et al
    Management of lung cancer screening results based on individual prediction of current and future lung cancer risk.
    J Thorac Oncol. 2021 Oct 11. pii: S1556-0864(21)03244.
    PubMed     Abstract available


  39. HUO KG, Notsuda H, Fang Z, Liu NF, et al
    Lung cancer driven by BRAF(G469V) mutation is targetable by EGFR kinase inhibitors.
    J Thorac Oncol. 2021 Oct 11. pii: S1556-0864(21)03205.
    PubMed     Abstract available


  40. SONG Z, Lian S, Mak S, Chow MZ, et al
    Deep RNA sequencing revealed fusion junctional heterogeneity may predict crizotinib treatment efficacy in ALK-rearranged non-small cell lung cancer.
    J Thorac Oncol. 2021 Oct 6. pii: S1556-0864(21)03219.
    PubMed     Abstract available


  41. DZIADZIUSZKO R, Didkowska J, Jassem J
    Authors' Reply to Role of Primary Prevention in Lung Cancer Control in Poland.
    J Thorac Oncol. 2021;16:e94-e95.
    PubMed    


  42. ZATONSKI WA, Janik-Koncewicz K, Zatonski M
    Role of Primary Prevention in Lung Cancer Control in Poland.
    J Thorac Oncol. 2021;16:e93-e94.
    PubMed    


  43. OCAK S, Tournoy K, Berghmans T, Demedts I, et al
    Lung Cancer in Belgium.
    J Thorac Oncol. 2021;16:1610-1621.
    PubMed    


  44. TSIM S, Alexander L, Kelly C, Shaw A, et al
    Serum Proteomics and Plasma Fibulin-3 in Differentiation of Mesothelioma From Asbestos-Exposed Controls and Patients With Other Pleural Diseases.
    J Thorac Oncol. 2021;16:1705-1717.
    PubMed     Abstract available


    September 2021
  45. SALEH MM, Scheffler M, Merkelbach-Bruse S, Scheel AH, et al
    Comprehensive Analysis of TP53 and KEAP1 Mutations and their Impact on Survival in Localized and Advanced Stage Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2021 Sep 30. pii: S1556-0864(21)03187.
    PubMed     Abstract available


  46. QU S, Fetsch P, Thomas A, Pommier Y, et al
    Molecular Subtypes of Primary Small Cell Lung Cancer Tumors and Their Associations with Neuroendocrine and Therapeutic Markers.
    J Thorac Oncol. 2021 Sep 14. pii: S1556-0864(21)03186.
    PubMed     Abstract available


  47. NISHINO M, Hatabu H, Ricciuti B, Vaz V, et al
    Brief Report Axillary lymphadenopathy after COVID-19 vaccinations in patients with thoracic malignancy: Incidence, predisposing factors, and imaging characteristics.
    J Thorac Oncol. 2021 Sep 7. pii: S1556-0864(21)03184.
    PubMed     Abstract available


  48. BESTVINA CM, Pointer KB, Karrison T, Al-Hallaq H, et al
    A Phase I Trial of Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients with Stage IV Non-Small Cell Lung Cancer (COSINR Study).
    J Thorac Oncol. 2021 Sep 6. pii: S1556-0864(21)02441.
    PubMed     Abstract available


  49. TRAN HTT, Nguyen S, Nguyen KK, Pham DX, et al
    Lung Cancer in Vietnam.
    J Thorac Oncol. 2021;16:1443-1448.
    PubMed    


  50. SINGH AK, Sands JM
    Yet Another Reminder of the Value of Lung Cancer Screening.
    J Thorac Oncol. 2021;16:1437-1439.
    PubMed    


  51. ZHAO H, Zhang Z, Zhang L
    Response to: The Role of Dual Inhibition of EGFR and Vascular EGF(R) in the Treatment of NSCLC With EGFR Mutation.
    J Thorac Oncol. 2021;16:e72-e76.
    PubMed    


  52. YAMAOKA T, Kim YH, Iwatsubo S, Nishimura Y, et al
    The Role of Dual Inhibition of EGFR and Vascular Endothelial Growth Factor (Receptor) in the Treatment of NSCLC With EGFR Mutation.
    J Thorac Oncol. 2021;16:e71-e72.
    PubMed    


  53. BORZI C, Caiola E, Ganzinelli M, Centonze G, et al
    miR-17 Epigenetic Modulation of LKB1 Expression in Tumor Cells Uncovers a New Group of Patients With Poor-Prognosis NSCLC.
    J Thorac Oncol. 2021;16:e68-e70.
    PubMed    


  54. BI G, Liang J, Shan G, Zhan C, et al
    Some Thoughts Concerning the Mutational Background of Cell Lines and Heterogeneity of Bulk Tumor.
    J Thorac Oncol. 2021;16:e67-e68.
    PubMed    


  55. LEE HY
    A Wake-Up Call for Immune Checkpoint Inhibitor-Related Pneumonitis.
    J Thorac Oncol. 2021;16:1440-1442.
    PubMed    


  56. BIRONZO P, Passiglia F, Novello S
    Winds From the ORIENT: New Data to Inform RATIONAL Choice?
    J Thorac Oncol. 2021;16:1434-1436.
    PubMed    


  57. UPRETY D, Remon J, Adjei AA
    All That Glitters Is Not Gold: The Story of Rovalpituzumab Tesirine in SCLC.
    J Thorac Oncol. 2021;16:1429-1433.
    PubMed    


  58. LIAO BC, Chih-Hsin Yang J
    Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:1426-1428.
    PubMed    


  59. NAKASHIMA K, Tsubata Y, Niihara H, Araki A, et al
    Palm Pustules Induced by Pemetrexed.
    J Thorac Oncol. 2021;16:1589-1591.
    PubMed    


  60. POZZESSERE C, Lazor R, Jumeau R, Peters S, et al
    Imaging Features of Pulmonary Immune-related Adverse Events.
    J Thorac Oncol. 2021;16:1449-1460.
    PubMed     Abstract available


  61. VANDENHOECK J, van Meerbeeck JP, Fransen E, Raskin J, et al
    DNA Methylation as a Diagnostic Biomarker for Malignant Mesothelioma: A Systematic Review and Meta-Analysis.
    J Thorac Oncol. 2021;16:1461-1478.
    PubMed     Abstract available


    August 2021
  62. CAMIDGE DR, Kim HR, Ahn MJ, Yang JC, et al
    Brigatinib versus Crizotinib in Anaplastic Lymphoma Kinase (ALK) Inhibitor-Naive Advanced ALK-Positive Non-Small Cell Lung Cancer: Final Results of the Phase 3 ALTA-1L Trial.
    J Thorac Oncol. 2021 Aug 30. pii: S1556-0864(21)02398.
    PubMed     Abstract available


  63. DOROSHOW DB, Wei W, Gupta S, Zugazagoitia J, et al
    PD-L1 tumor proportion score and overall survival from first-line pembrolizumab in patients with nonsquamous versus squamous non-small cell lung cancer.
    J Thorac Oncol. 2021 Aug 26. pii: S1556-0864(21)02392.
    PubMed     Abstract available


  64. PLANCHARD D, Besse B, Groen HJM, Hashemi SMS, et al
    Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic non-small cell lung cancer: Updated 5-year survival rates and genomic analysis.
    J Thorac Oncol. 2021 Aug 26. pii: S1556-0864(21)02403.
    PubMed     Abstract available


  65. THOMAS NJ, Myall NJ, Sun F, Patil T, et al
    Brain Metastases in EGFR- and ALK-positive Non-Small Cell Lung Cancer: Outcomes of CNS Penetrant Tyrosine Kinase Inhibitors (TKIs) Alone versus in Combination with Radiation.
    J Thorac Oncol. 2021 Aug 26. pii: S1556-0864(21)02401.
    PubMed     Abstract available


  66. KERPEL-FRONIUS A, Tammemagi M, Cavic M, Henschke C, et al
    Screening for lung cancer in individuals who never smoked: An IASLC Early Detection and Screening Committee Report.
    J Thorac Oncol. 2021 Aug 26. pii: S1556-0864(21)02391.
    PubMed     Abstract available


  67. SHIRASAWA M, Yoshida T, Shimoda Y, Takayanagi D, et al
    Differential Immune-Related Microenvironment Determines PD-1/PD-L1 Blockade Efficacy in Advanced Non-Small Cell Lung Cancer Patients.
    J Thorac Oncol. 2021 Aug 19. pii: S1556-0864(21)02373.
    PubMed     Abstract available


  68. YAMAGUCHI H, Wakuda K, Fukuda M, Kenmotsu H, et al
    A phase II study of osimertinib for radiotherapy-naive CNS metastasis from non-small cell lung cancer: Results for the T790M cohort of the OCEAN study (LOGIK1603/WJOG9116L).
    J Thorac Oncol. 2021 Aug 19. pii: S1556-0864(21)02372.
    PubMed     Abstract available


  69. WALIANY S, Zhu H, Wakelee H, Padda SK, et al
    Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma.
    J Thorac Oncol. 2021 Aug 18. pii: S1556-0864(21)02377.
    PubMed     Abstract available


  70. QUAIFE SL, Dickson JL, Brain KE, Kurtidu C, et al
    Psychological targets for lung cancer screening uptake: a prospective longitudinal cohort study.
    J Thorac Oncol. 2021 Aug 14. pii: S1556-0864(21)02369.
    PubMed     Abstract available


  71. HERZOG BH, Devarakonda S, Govindan R
    Overcoming chemotherapy resistance in Small Cell Lung Cancer.
    J Thorac Oncol. 2021 Aug 3. pii: S1556-0864(21)02333.
    PubMed    


  72. AREDO JV, Wakelee HA, Han SS
    A Moving Target: Integration of Smoking Cessation Into Screening for Second Primary Lung Cancer.
    J Thorac Oncol. 2021;16:e59-e60.
    PubMed    


  73. PELOSI G, Pasini F
    Over-Time Risk of Lung Cancer Is Largely Owing to Continuing Smoking Exposition: A Good Reason to Quit.
    J Thorac Oncol. 2021;16:e57-e59.
    PubMed    


  74. SINGH N, Agrawal S, Jiwnani S, Khosla D, et al
    Lung Cancer in India.
    J Thorac Oncol. 2021;16:1250-1266.
    PubMed    


  75. BELDERBOS JSA, De Ruysscher DKM, De Jaeger K, Koppe F, et al
    Reaction on the Interpretation of the Hippocampus Avoidance Prophylactic Cranial Irradiation Trial in SCLC (NCT01780675).
    J Thorac Oncol. 2021;16:e63-e65.
    PubMed    


  76. MLADKOVA N, Lo S, Brown PD, Gondi V, et al
    Hippocampal Avoidance Prophylactic Cranial Irradiation: Interpreting the Evidence.
    J Thorac Oncol. 2021;16:e60-e63.
    PubMed    


  77. COOPER WA, Lantuejoul S, Mino-Kenudson M
    Predicting Response to Programmed Cell Death Protein-1 or Programmed Death-Ligand 1 Blockade in NSCLC-Is Multiplex Immunohistochemistry or Immunofluorescence the Answer?
    J Thorac Oncol. 2021;16:1247-1249.
    PubMed    


  78. RUIZ J, Chan M, Strowd RE
    Treatment of Leptomeningeal Metastases: New Hammer, the Same Nail.
    J Thorac Oncol. 2021;16:1244-1246.
    PubMed    


  79. SMIT EF, Belderbos J
    Concurrent Chemoradiation, Adjuvant Durvalumab, and KEAP-1/NRF-2 Mutations: A Happy Marriage?
    J Thorac Oncol. 2021;16:1242-1243.
    PubMed    


  80. COLOMBO M, Ndembe G, Broggini M
    KRAS Targeting and Resistance: Anticipating the Expectable.
    J Thorac Oncol. 2021;16:1239-1241.
    PubMed    


  81. HUDDAR P, Califano R
    Poly(Adenosine Diphosphate-Ribose) Polymerase Inhibition as Maintenance Treatment for SCLC: The Search Must Continue.
    J Thorac Oncol. 2021;16:1236-1238.
    PubMed    


  82. SHAVERDIAN N, Offin M, Shepherd AF, Simone CB 2nd, et al
    The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KEAP1-NFE2L2-Mutant Tumors.
    J Thorac Oncol. 2021;16:1392-1402.
    PubMed     Abstract available


  83. FAN C, Zhao Q, Li L, Shen W, et al
    Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC-a Prospective, Open-Label, Single-Arm Phase 1/2 Clinical Trial (Unique Identifier:
    J Thorac Oncol. 2021;16:1359-1368.
    PubMed     Abstract available


  84. YEONG J, Suteja L, Simoni Y, Lau KW, et al
    Intratumoral CD39(+)CD8(+) T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLC.
    J Thorac Oncol. 2021;16:1349-1358.
    PubMed     Abstract available


  85. KOGA T, Suda K, Fujino T, Ohara S, et al
    KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
    J Thorac Oncol. 2021;16:1321-1332.
    PubMed     Abstract available


  86. YOTSUKURA M, Asamura H, Motoi N, Kashima J, et al
    Long-Term Prognosis of Patients With Resected Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma of the Lung.
    J Thorac Oncol. 2021;16:1312-1320.
    PubMed     Abstract available


  87. BORZI C, Ganzinelli M, Caiola E, Colombo M, et al
    LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stress-Based Treatments.
    J Thorac Oncol. 2021;16:1298-1311.
    PubMed     Abstract available


    July 2021
  88. DZIADZIUSZKO R, Mok T, Peters S, Han JY, et al
    Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic Non-Small Cell Lung Cancer: Initial Results of the Phase 2 ALK-Positive Cohort.
    J Thorac Oncol. 2021 Jul 23. pii: S1556-0864(21)02321.
    PubMed     Abstract available


  89. PATEL SA, Herynk MH, Cascone T, Saigal B, et al
    Estrogen promotes resistance to bevacizumab in murine models of non-small cell lung cancer.
    J Thorac Oncol. 2021 Jul 23. pii: S1556-0864(21)02320.
    PubMed     Abstract available


  90. SOCINSKI MA, Nishio M, Jotte RM, Cappuzzo F, et al
    IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer.
    J Thorac Oncol. 2021 Jul 23. pii: S1556-0864(21)02322.
    PubMed     Abstract available


  91. SMELTZER MP, Lee YS, Faris NR, Fehnel C, et al
    Trends in Accuracy and Comprehensiveness of Pathology Reports for Resected Non-small Cell Lung Cancer (NSCLC) in a High Mortality Area of the United States.
    J Thorac Oncol. 2021 Jul 16. pii: S1556-0864(21)02299.
    PubMed     Abstract available


  92. STEWART CA, Gay CM, Ramkumar K, Cargill KR, et al
    Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology.
    J Thorac Oncol. 2021 Jul 15. pii: S1556-0864(21)02294.
    PubMed     Abstract available


  93. JASSEM J, de Marinis F, Giaccone G, Vergnenegre A, et al
    Updated Overall Survival Analysis From IMpower110: Atezolizumab versus Platinum-Based Chemotherapy in Treatment-Naive PD-L1-Selected Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2021 Jul 12. pii: S1556-0864(21)02286.
    PubMed     Abstract available


  94. AI X, Wang Q, Cheng Y, Liu X, et al
    Safety but Limited Efficacy of Ensartinib in ROS1-Positive Non-small Cell Lung Cancer: A Single-arm, Multicenter Phase II study.
    J Thorac Oncol. 2021 Jul 12. pii: S1556-0864(21)02290.
    PubMed     Abstract available


  95. POWELL SF, Rodriguez-Abreu D, Langer CJ, Tafreshi A, et al
    Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, 189, and 407.
    J Thorac Oncol. 2021 Jul 12. pii: S1556-0864(21)02287.
    PubMed     Abstract available


  96. MYERS R, Brauer M, Dummer T, Atkar-Khattra S, et al
    High Ambient Air Pollution Exposure Among Never Smokers Versus Ever Smokers with Lung Cancer.
    J Thorac Oncol. 2021 Jul 10. pii: S1556-0864(21)02256.
    PubMed     Abstract available


  97. WANG Y, Li J, Chang S, Dong Y, et al
    Risk and influencing factors for subsequent primary lung cancer after treatment of breast cancer: a systematic review and two meta-analyses based on four million cases.
    J Thorac Oncol. 2021 Jul 10. pii: S1556-0864(21)02293.
    PubMed     Abstract available


  98. ROLFO C, Mack P, Scagliotti GV, Aggarwal C, et al
    Liquid Biopsy for Advanced Non-Small Cell Lung Cancer: A Consensus Statement from The International Association for the Study of Lung Cancer (IASLC).
    J Thorac Oncol. 2021 Jul 8. pii: S1556-0864(21)02284.
    PubMed    


  99. HANN CL, Burns TF, Dowlati A, Morgensztern D, et al
    Brief Report: A Phase 1 Study Evaluating Rovalpituzumab Tesirine (Rova-T) in Frontline Treatment of Patients With Extensive-Stage Small Cell Lung Cancer.
    J Thorac Oncol. 2021 Jul 6. pii: S1556-0864(21)02289.
    PubMed     Abstract available


  100. PARK HR, Kim TM, Lee Y, Kim S, et al
    Acquired resistance to third-generation EGFR tyrosine kinase inhibitors in patients with de novo EGFR(T790M)-mutant non-small cell lung cancer.
    J Thorac Oncol. 2021 Jul 6. pii: S1556-0864(21)02254.
    PubMed     Abstract available


  101. KUMAR A, Kumar S, Gilja S, Potter A, et al
    Reconsidering the American Joint Committee on Cancer 8(th) Edition TNM Staging Manual Classifications for T2b/T3 Non-small-cell Lung Cancer.
    J Thorac Oncol. 2021 Jul 6. pii: S1556-0864(21)02283.
    PubMed     Abstract available


  102. MOUNTZIOS G, Gkiozos I, Stratakos G, Pissakas G, et al
    Lung Cancer in Greece.
    J Thorac Oncol. 2021;16:1058-1066.
    PubMed    


  103. UGUEN A
    Each RET Break-Apart Fluorescence In Situ Hybridization Probe Requires Proper Interpretation Criteria.
    J Thorac Oncol. 2021;16:e55.
    PubMed    


  104. ZHU VW, Zhang SS, Zhang J, Swensen J, et al
    Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET-positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib.
    J Thorac Oncol. 2021;16:e51-e54.
    PubMed    


  105. DOWLATI A, Chan T
    Pursuing Immunotherapeutic Targets in SCLC.
    J Thorac Oncol. 2021;16:1056-1057.
    PubMed    


  106. GRANNIS FW JR
    Do Cancer Screening Researchers Have a Continuing Ethical Obligation to Their Study Subjects?
    J Thorac Oncol. 2021;16:1053-1055.
    PubMed    



  107. Dr. Gouri Shankar Bhattacharyya, MD, PhD, FRCP: In Memoriam (October 31, 1958-May 1, 2021).
    J Thorac Oncol. 2021;16:1043-1044.
    PubMed    


  108. LE-RADEMACHER J, Wang X
    Time-To-Event Data: An Overview and Analysis Considerations.
    J Thorac Oncol. 2021;16:1067-1074.
    PubMed     Abstract available


  109. GOODWIN D, Rathi V, Conron M, Wright GM, et al
    Genomic and Clinical Significance of Multiple Primary Lung Cancers as Determined by Next-Generation Sequencing.
    J Thorac Oncol. 2021;16:1166-1175.
    PubMed     Abstract available


  110. YANG SR, Chang JC, Leduc C, Tan KS, et al
    Invasive Mucinous Adenocarcinomas With Spatially Separate Lung Lesions: Analysis of Clonal Relationship by Comparative Molecular Profiling.
    J Thorac Oncol. 2021;16:1188-1199.
    PubMed     Abstract available


  111. LINDBERG K, Grozman V, Karlsson K, Lindberg S, et al
    The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy.
    J Thorac Oncol. 2021;16:1200-1210.
    PubMed     Abstract available


  112. HAN DH, Duan F, Wu Y, Goo JM, et al
    Clinical Significance of Lung-RADS Category 3 Lesions in the National Lung Screening Trial.
    J Thorac Oncol. 2021;16:1118-1126.
    PubMed     Abstract available


    June 2021
  113. WARREN GW, Lim VS, Chowdhary M, Marwaha G, et al
    Brief Report: New Pulmonary Infiltrates Observed on Computed Tomography Based Image Guidance for Radiotherapy Warrant Diagnostic Workup for COVID-19.
    J Thorac Oncol. 2021 Jun 21. pii: S1556-0864(21)02232.
    PubMed     Abstract available


  114. AKAMATSU H, Murakami H, Harada H, Shimizu J, et al
    Gefitinib with concurrent thoracic radiotherapy in unresectable locally advanced non-small cell lung cancer with EGFR mutation; West Japan Oncology Group 6911L.
    J Thorac Oncol. 2021 Jun 8. pii: S1556-0864(21)02190.
    PubMed     Abstract available


  115. SU CC, Wu JT, Neal JW, Popat RA, et al
    Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis.
    J Thorac Oncol. 2021 Jun 3. pii: S1556-0864(21)02181.
    PubMed     Abstract available


  116. ANG YLE, Chia PL, Chua KLM, Devanand A, et al
    Lung Cancer in Singapore.
    J Thorac Oncol. 2021;16:906-911.
    PubMed    


  117. RAMI-PORTA R, Goldstraw P, Asamura H
    Commemorating the Silver Anniversary of the International Association for the Study of Lung Cancer International Workshop on Intrathoracic Staging.
    J Thorac Oncol. 2021;16:902-905.
    PubMed    


  118. GRASS GD, Scott JG, Sedor G, Kattan MW, et al
    Response to: Noncancer Cells in Tumor Samples May Bias the Predictive Genomically Adjusted Radiation Dose.
    J Thorac Oncol. 2021;16:e48-e49.
    PubMed    


  119. DU Y, Hu Z, Liang J, Zhan C, et al
    Noncancer Cells in Tumor Samples May Bias the Predictive Genomic-Adjusted Radiation Dose.
    J Thorac Oncol. 2021;16:e47.
    PubMed    


  120. RYAN BM
    In Response: Using Propensity Score Matching to Balance the Baseline Characteristics.
    J Thorac Oncol. 2021;16:e46.
    PubMed    


  121. LIANG J, Hu Z, Zhan C, Wang Q, et al
    Using Propensity Score Matching to Balance the Baseline Characteristics.
    J Thorac Oncol. 2021;16:e45-e46.
    PubMed    


  122. BELDERBOS JSA, De Ruysscher DKM, De Jaeger K, Koppe F, et al
    Why Did the Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC Not Reveal a Difference?
    J Thorac Oncol. 2021;16:e42-e45.
    PubMed    


  123. BREEN WG, Brown PD, Laack NN
    Hippocampal Avoidance Prophylactic Cranial Irradiation for SCLC.
    J Thorac Oncol. 2021;16:e41-e42.
    PubMed    


  124. DEUTSCH E, Cengel KA, Galluzzi L, Levy A, et al
    Could Protons Promote Tumor Control by Avoiding Lymphopenia?
    J Thorac Oncol. 2021;16:e39-e41.
    PubMed    


  125. BAUMAN J, Borghaei H
    To Give or Not to Give: Consolidative Durvalumab in EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:894-896.
    PubMed    


  126. WARREN GW, Evans WK, Dresler C
    Critical Determinants of Cancer Treatment Outcomes: Smoking Must Be Addressed at the Highest Levels in Cancer Care.
    J Thorac Oncol. 2021;16:891-893.
    PubMed    


  127. CAMIDGE DR, Otterson GA, Clark JW, Ignatius Ou SH, et al
    Crizotinib in Patients With MET-Amplified NSCLC.
    J Thorac Oncol. 2021;16:1017-1029.
    PubMed     Abstract available


  128. FINN SP, Addeo A, Dafni U, Thunnissen E, et al
    Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project.
    J Thorac Oncol. 2021;16:990-1002.
    PubMed     Abstract available


  129. STEUER CE, Jegede OA, Dahlberg SE, Wakelee HA, et al
    Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial.
    J Thorac Oncol. 2021;16:960-967.
    PubMed     Abstract available


    May 2021
  130. JAZIEH AR, Onal HC, Weng Tan DS, Soo RA, et al
    Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: Results of KINDLE, a multi-country observational study.
    J Thorac Oncol. 2021 May 26. pii: S1556-0864(21)02174.
    PubMed     Abstract available


  131. ZHOU C, Wu L, Fan Y, Wang Z, et al
    Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous non-small-cell lung cancer: results from a randomized, double-blind, phase 3 trial (ORIENT-12).
    J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02128.
    PubMed     Abstract available


  132. HERBST RS, Garon EB, Kim DW, Cho BC, et al
    5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death Ligand 1-Positive Advanced Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02172.
    PubMed     Abstract available


  133. JOHNSON AM, Boland JM, Wrobel J, Klezcko EK, et al
    Cancer cell-specific MHCII expression as a determinant of the immune infiltrate organization and function in the non-small cell lung cancer tumor microenvironment.
    J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02175.
    PubMed     Abstract available


  134. BARBI J, Patnaik SK, Pabla S, Zollo R, et al
    Visceral Obesity Promotes Lung Cancer Progression-Toward Resolution of the Obesity Paradox in Lung Cancer.
    J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02171.
    PubMed     Abstract available


  135. LU S, Wang J, Yu Y, Yu X, et al
    Tislelizumab Plus Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (RATIONALE 304): A Randomized Phase 3 Trial.
    J Thorac Oncol. 2021 May 22. pii: S1556-0864(21)02176.
    PubMed     Abstract available


  136. ZHAO H, Yao W, Min X, Gu K, et al
    Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant non-small cell lung cancer: the phase III ACTIVE study (CTONG1706).
    J Thorac Oncol. 2021 May 22. pii: S1556-0864(21)02177.
    PubMed     Abstract available


  137. LOIOLA DE ALENCAR VT, Camandaroba MPG, Pirolli R, Fogassa CAZ, et al
    Immunotherapy as Single Treatment for Non-small-cell Lung Cancer Patients with Brain Metastases: a systematic review and meta-analysis - the META-L-BRAIN study.
    J Thorac Oncol. 2021 May 5. pii: S1556-0864(21)02131.
    PubMed     Abstract available


  138. OSAROGIAGBON RU, Ray MA, Faris NR, Smeltzer MP, et al
    Response to: "Lymph Node Dissection for Non-Small-Cell Lung Cancer at Whose Discretion?"
    J Thorac Oncol. 2021;16:e36-e37.
    PubMed    


  139. PIRKER R, Prosch H, Popper H, Klepetko W, et al
    Lung Cancer in Austria.
    J Thorac Oncol. 2021;16:725-733.
    PubMed    


  140. KIM CG, Cho BC, Lim SM
    Sequencing of MET Inhibitors in Lung Cancer: Have We Met the Target?
    J Thorac Oncol. 2021;16:709-711.
    PubMed    


  141. LI M, Zhan C, Wang Q
    Is the Story of M Descriptors Fulfilled or Finished?
    J Thorac Oncol. 2021;16:e36-e37.
    PubMed    


  142. METOVIC J, Bianchi F, Barella M, Papotti M, et al
    SMARCA2 Deficiency While Preserving SMARCA4 and SMARCB1 in Lung Neuroendocrine Carcinomas.
    J Thorac Oncol. 2021;16:e32-e35.
    PubMed    


  143. DE CARLO E, Schiappacassi M, Del Conte A, Stanzione B, et al
    Combination of Chemotherapy and ALK Inhibitors in ALK-Positive NSCLC.
    J Thorac Oncol. 2021;16:e31-e32.
    PubMed    


  144. NISHIO M, Mendus D, Wang L, Socinski MA, et al
    Response to Letter to the Editor.
    J Thorac Oncol. 2021;16:e30-e31.
    PubMed    


  145. DI FEDERICO A, Nuvola G, Deiana C, Donati G, et al
    IMpower 132: Is the Second Exception to the Rule No Longer an Exception?
    J Thorac Oncol. 2021;16:e29-e30.
    PubMed    


  146. SEDOR G, Scott JG, Kattan MW, Torres-Roca JF, et al
    Letter Response.
    J Thorac Oncol. 2021;16:e28-e29.
    PubMed    


  147. MISTRY HB
    Simulating RTOG 0617 using Genomic Adjusted Radiation Dose: Comparing Apples With Oranges.
    J Thorac Oncol. 2021;16:e27.
    PubMed    


  148. RIMNER A, Wu AJ, Grills IS
    What Is the Impact of Hippocampus Avoidance-Prophylactic Cranial Irradiation on Neurocognitive Preservation?
    J Thorac Oncol. 2021;16:722-724.
    PubMed    


  149. WESTEEL V
    Surveillance After Curative-Intent Treatment for NSCLC: More to It Than Meets the Eye.
    J Thorac Oncol. 2021;16:719-721.
    PubMed    


  150. JULOORI A, Vokes EE
    Beyond PACIFIC: Uncharted Waters.
    J Thorac Oncol. 2021;16:715-718.
    PubMed    


  151. LIU SY, Wu YL
    Unmet Clinical Demand for Patients With Unresectable Stage III NSCLC Having Actionable Genetic Alterations.
    J Thorac Oncol. 2021;16:712-714.
    PubMed    


  152. ADJEI AA, Ignatius Ou SH, Ho C, Pujol JL, et al
    Increasing Transparency in Author Contributions to Manuscripts: Enhanced Policy on Ghost and Honorary Authorships.
    J Thorac Oncol. 2021;16:706-708.
    PubMed    


  153. MATSUI S, Le-Rademacher J, Mandrekar SJ
    Statistical Models in Clinical Studies.
    J Thorac Oncol. 2021;16:734-739.
    PubMed     Abstract available


  154. STIRLING RG, Chau C, Shareh A, Zalcberg J, et al
    Effect of Follow-Up Surveillance After Curative-Intent Treatment of NSCLC on Detection of New and Recurrent Disease, Retreatment, and Survival: A Systematic Review and Meta-Analysis.
    J Thorac Oncol. 2021;16:784-797.
    PubMed     Abstract available


  155. BELDERBOS JSA, De Ruysscher DKM, De Jaeger K, Koppe F, et al
    Phase 3 Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC (NCT01780675).
    J Thorac Oncol. 2021;16:840-849.
    PubMed     Abstract available


  156. HELLYER JA, Aredo JV, Das M, Ramchandran K, et al
    Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC.
    J Thorac Oncol. 2021;16:868-872.
    PubMed     Abstract available


  157. FAIVRE-FINN C, Vicente D, Kurata T, Planchard D, et al
    Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.
    J Thorac Oncol. 2021;16:860-867.
    PubMed     Abstract available


  158. NAGASAKA M, Zhu VW, Lim SM, Greco M, et al
    Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC.
    J Thorac Oncol. 2021;16:740-763.
    PubMed     Abstract available


  159. PASSARO A, Mok T, Peters S, Popat S, et al
    Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations.
    J Thorac Oncol. 2021;16:764-773.
    PubMed     Abstract available


    April 2021
  160. AI X, Pan Y, Shi J, Yang N, et al
    Efficacy and Safety of Niraparib as Maintenance Treatment in Patients with Extensive-Stage Small Cell Lung Cancer after First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.
    J Thorac Oncol. 2021 Apr 26. pii: S1556-0864(21)02111.
    PubMed     Abstract available


  161. YONESHIMA Y, Morita S, Ando M, Nakamura A, et al
    Phase 3 trial comparing nab-paclitaxel with docetaxel for previously treated advanced non-small cell lung cancer.
    J Thorac Oncol. 2021 Apr 26. pii: S1556-0864(21)02107.
    PubMed     Abstract available


  162. HWANG DM, Albaqer T, Santiago RC, Weiss J, et al
    Prevalence and heterogeneity of PD-L1 expression by 22C3 assay in routine population-based and reflexive clinical testing in lung cancer.
    J Thorac Oncol. 2021 Apr 26. pii: S1556-0864(21)02108.
    PubMed     Abstract available


  163. QIAO M, Jiang T, Liu X, Mao S, et al
    Immune checkpoint inhibitors in EGFR-mutated non-small cell lung cancer: Dusk or Dawn?
    J Thorac Oncol. 2021 Apr 26. pii: S1556-0864(21)02113.
    PubMed     Abstract available


  164. ANDRUSKA N, Stowe HB, Crockett C, Liu W, et al
    Stereotactic Radiation for Lung Cancer: A Practical Approach to Challenging Scenarios.
    J Thorac Oncol. 2021 Apr 23. pii: S1556-0864(21)02112.
    PubMed     Abstract available


  165. SAFIRI S, Sohrabi MR, Carson-Chahhoud K, Bettampadi D, et al
    Burden of tracheal, bronchus and lung cancer and its attributable risk factors in 204 countries and territories, 1990-2019.
    J Thorac Oncol. 2021 Apr 15. pii: S1556-0864(21)02110.
    PubMed     Abstract available


  166. PATAER A, Weissferdt A, Vaporciyan AA, Correa AM, et al
    Evaluation of Pathologic Response in Lymph Nodes of Lung Cancer Patients Receiving Neoadjuvant Chemotherapy.
    J Thorac Oncol. 2021 Apr 12. pii: S1556-0864(21)02109.
    PubMed     Abstract available


  167. BAUMEISTER SE, Baurecht H, Nolde M, Alayash Z, et al
    Cannabis use, pulmonary function, and lung cancer susceptibility: A Mendelian randomization study.
    J Thorac Oncol. 2021 Apr 11. pii: S1556-0864(21)02105.
    PubMed     Abstract available


  168. MEMMOTT RM, Wolfe AR, Carbone DP, Williams TM, et al
    Predictors of Response, Progression Free Survival, and Overall Survival in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
    J Thorac Oncol. 2021 Apr 9. pii: S1556-0864(21)02072.
    PubMed     Abstract available


  169. PARK K, Ozguroglu M, Vansteenkiste J, Spigel D, et al
    Avelumab vs docetaxel in patients with platinum-treated advanced non-small-cell lung cancer: 2-year follow-up from the JAVELIN Lung 200 phase 3 trial.
    J Thorac Oncol. 2021 Apr 9. pii: S1556-0864(21)01832.
    PubMed     Abstract available


  170. ALESSI JV, Ricciuti B, Spurr LF, Gupta H, et al
    SMARCA4 and other SWI/SNF family genomic alterations in non-small cell lung cancer: Clinicopathological characteristics and outcomes to immune checkpoint inhibition.
    J Thorac Oncol. 2021 Apr 9. pii: S1556-0864(21)02104.
    PubMed     Abstract available


  171. LIU L, Bai H, Wang C, Seery S, et al
    Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
    J Thorac Oncol. 2021 Apr 8. pii: S1556-0864(21)02071.
    PubMed     Abstract available


  172. ODINTSOV I, Mattar MS, Lui AJW, Offin M, et al
    Novel preclinical patient-derived lung cancer models reveal inhibition of HER3 and MTOR signaling as therapeutic strategies for NRG1 fusion-positive cancers.
    J Thorac Oncol. 2021 Apr 8. pii: S1556-0864(21)02068.
    PubMed     Abstract available


  173. THOMAS PL, Groves SM, Zhang YK, Li J, et al
    Beyond PD-L1: B7-H6 emerges as a potential immunotherapy target in small cell lung cancer.
    J Thorac Oncol. 2021 Apr 8. pii: S1556-0864(21)02066.
    PubMed     Abstract available


  174. JOHNSON ML, Zvirbule Z, Laktionov K, Helland A, et al
    Rovalpituzumab Tesirine as a Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From the Phase 3 MERU Study.
    J Thorac Oncol. 2021 Apr 3. pii: S1556-0864(21)02067.
    PubMed     Abstract available


  175. LUO YH, Chiu CH, Scott Kuo CH, Chou TY, et al
    Lung Cancer in Republic of China.
    J Thorac Oncol. 2021;16:519-527.
    PubMed    


  176. GOTO T
    Lymph Node Dissection for NSCLC at Whose Discretion?
    J Thorac Oncol. 2021;16:e25.
    PubMed    


  177. PAZ-ARES L
    Response to: Bintrafusp Alfa in Second-Line Treatment of Patients With NSCLC.
    J Thorac Oncol. 2021;16:e24.
    PubMed    


  178. XU J, Nie H, Wan H
    Bintrafusp Alfa in the Second-Line Treatment of Patients With NSCLC.
    J Thorac Oncol. 2021;16:e23-e24.
    PubMed    


  179. QIU H, Li Q, Xiao Y, Wu D, et al
    A Novel Intergenic Region Between KLHL31 and LRRC1-ALK Exon 20 Fusion Variant in Advanced Lung Adenocarcinoma and its Remarkable Response to ALK Inhibitor.
    J Thorac Oncol. 2021;16:e21-e23.
    PubMed    


  180. NAGASAKA M, Ou SI
    Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC.
    J Thorac Oncol. 2021;16:532-536.
    PubMed    


  181. CAMIDGE DR
    Lorlatinib Should Not be Considered as the Preferred First-Line Option in Patients With Advanced ALK Rearranged NSCLC.
    J Thorac Oncol. 2021;16:528-531.
    PubMed    


  182. GADGEEL SM
    Patient-Reported Outcomes in the Era of Immunotherapy Trials.
    J Thorac Oncol. 2021;16:516-518.
    PubMed    


  183. FALKSON CB
    Postoperative Radiation for Completely Resected Stage II/III Thymoma: What Do We Know in 2021?
    J Thorac Oncol. 2021;16:515.
    PubMed    


  184. PATEL SP, Kelly K
    IMpower 132: Loses Power at the Finish Line.
    J Thorac Oncol. 2021;16:512-514.
    PubMed    


  185. PACHECO JM, Schenk EL
    CD73 and Adenosine Receptor Signaling as a Potential Therapeutic Target in EGFR-Mutated NSCLC.
    J Thorac Oncol. 2021;16:509-511.
    PubMed    


  186. SEBASTIAN M, Stratmann JA, Eberhardt WEE
    Too Good to be True?
    J Thorac Oncol. 2021;16:507-508.
    PubMed    


  187. LE X
    Heterogeneity in MET-Aberrant NSCLC.
    J Thorac Oncol. 2021;16:504-506.
    PubMed    


  188. OU FS, Michiels S, Shyr Y, Adjei AA, et al
    Biomarker Discovery and Validation: Statistical Considerations.
    J Thorac Oncol. 2021;16:537-545.
    PubMed     Abstract available


  189. TATEISHI Y, Horita N, Namkoong H, Enomoto T, et al
    Postoperative Radiotherapy for Completely Resected Masaoka/Masaoka-Koga Stage II/III Thymoma Improves Overall Survival: An Updated Meta-Analysis of 4746 Patients.
    J Thorac Oncol. 2021;16:677-685.
    PubMed     Abstract available


  190. LE X, Negrao MV, Reuben A, Federico L, et al
    Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target.
    J Thorac Oncol. 2021;16:583-600.
    PubMed     Abstract available


  191. LAM VK, Zhang J, Wu CC, Tran HT, et al
    Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC.
    J Thorac Oncol. 2021;16:601-609.
    PubMed     Abstract available


  192. VILLALBA JA, Shih AR, Sayo TMS, Kunitoki K, et al
    Accuracy and Reproducibility of Intraoperative Assessment on Tumor Spread Through Air Spaces in Stage 1 Lung Adenocarcinomas.
    J Thorac Oncol. 2021;16:619-629.
    PubMed     Abstract available


  193. MOONEN L, Derks JL, Hermans BCM, Bunnik IM, et al
    Preoperative Biopsy Diagnosis in Pulmonary Carcinoids, a Shot in the Dark.
    J Thorac Oncol. 2021;16:610-618.
    PubMed     Abstract available


    March 2021
  194. SCARFONE G, Fumagalli M, Imbimbo M, Ceruti T, et al
    First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report.
    J Thorac Oncol. 2021 Mar 29. pii: S1556-0864(21)01705.
    PubMed     Abstract available


  195. OSAROGIAGBON RU, Rami-Porta R, Tsao MS, Montuenga LM, et al
    The International Association for the Study of Lung Cancer (IASLC) Molecular Database Project: Objectives, Challenges and Opportunities.
    J Thorac Oncol. 2021 Mar 23. pii: S1556-0864(21)01781.
    PubMed    


  196. AREDO JV, Luo SJ, Gardner RM, Sanyal N, et al
    Tobacco Smoking and Risk of Second Primary Lung Cancer.
    J Thorac Oncol. 2021 Mar 12. pii: S1556-0864(21)01747.
    PubMed     Abstract available


  197. TANG WF, Wu M, Bao H, Xu Y, et al
    Timing and origins of local and distant metastases in lung cancer.
    J Thorac Oncol. 2021 Mar 12. pii: S1556-0864(21)01746.
    PubMed     Abstract available


  198. MINO-KENUDSON M, Le Stang N, Daigneault JB, Nicholson AG, et al
    IASLC Global Survey on PD-L1 Testing for Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2021 Mar 1. pii: S1556-0864(21)01732.
    PubMed     Abstract available


  199. HENDRIKS LEL, Dingemans AC, De Ruysscher DKM, Aarts MJ, et al
    Lung Cancer in the Netherlands.
    J Thorac Oncol. 2021;16:355-365.
    PubMed    


  200. DY GK, Prasad D, Kumar P, Attwood K, et al
    A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy.
    J Thorac Oncol. 2021;16:e19-e20.
    PubMed    


  201. YANG X, Li Y, Duan Q, Zhang Q, et al
    Identification of a Novel MET Exon 14 Skipping Variant in Lung Adenocarcinoma Sensitive to Crizotinib Treatment.
    J Thorac Oncol. 2021;16:e17-e19.
    PubMed    


  202. SHIELDS MD, Hicks JK, Boyle TA, Haura EB, et al
    Selpercatinib Overcomes CCDC6-RET-Mediated Resistance to Osimertinib.
    J Thorac Oncol. 2021;16:e15-e17.
    PubMed    


  203. UPRETY D
    Osimertinib Should Not Yet Be Considered the Standard of Care for EGFR-Mutant NSCLC in the Adjuvant Setting.
    J Thorac Oncol. 2021;16:371-374.
    PubMed    


  204. REMON J, Hendriks LEL
    Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:368-370.
    PubMed    


  205. ADJEI AA
    Controversies in Thoracic Oncology.
    J Thorac Oncol. 2021;16:366-367.
    PubMed    


  206. RAJAN A
    Immunotherapy for Thymic Cancers: A Convoluted Path Toward a Cherished Goal.
    J Thorac Oncol. 2021;16:352-354.
    PubMed    


  207. SONG L, Xu Q, Lizaso A, Zhang Y, et al
    Brigatinib After Progression From Alectinib or Crizotinib: Paving the Way for Treatment Sequencing of ALK Inhibitors in ALK-Positive NSCLC.
    J Thorac Oncol. 2021;16:349-351.
    PubMed    


  208. SONG Z, Lu C, Xu CW, Zheng Z, et al
    Noncanonical Gene Fusions Detected at the DNA Level Necessitate Orthogonal Diagnosis Methods Before Targeted Therapy.
    J Thorac Oncol. 2021;16:344-348.
    PubMed    


  209. WANG X, Piantadosi S, Le-Rademacher J, Mandrekar SJ, et al
    Statistical Considerations for Subgroup Analyses.
    J Thorac Oncol. 2021;16:375-380.
    PubMed    


  210. NILSSON MB, Robichaux J, Herynk MH, Cascone T, et al
    Altered Regulation of HIF-1alpha in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype.
    J Thorac Oncol. 2021;16:439-451.
    PubMed     Abstract available


  211. NG TL, Johnson A, Nemenoff RA, Hsieh E, et al
    Prospective Observational Study Revealing Early Pulmonary Function Changes Associated With Brigatinib Initiation.
    J Thorac Oncol. 2021;16:486-491.
    PubMed     Abstract available


  212. LI W, Guo L, Liu Y, Dong L, et al
    Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
    J Thorac Oncol. 2021;16:404-418.
    PubMed     Abstract available


  213. GIACCONE G, Kim C
    Durable Response in Patients With Thymic Carcinoma Treated With Pembrolizumab After Prolonged Follow-Up.
    J Thorac Oncol. 2021;16:483-485.
    PubMed     Abstract available


  214. SECHI E, Zekeridou A
    Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies.
    J Thorac Oncol. 2021;16:381-394.
    PubMed     Abstract available


    February 2021
  215. MALHOTRA J, Nikolinakos P, Leal T, Lehman J, et al
    A Phase I/II Study of Rovalpituzumab Tesirine in Combination With Nivolumab +/- Ipilimumab in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer.
    J Thorac Oncol. 2021 Feb 27. pii: S1556-0864(21)01745.
    PubMed     Abstract available


  216. YAMADA Y, Simon-Keller K, Belharazem-Vitacolonnna D, Bohnenberger H, et al
    A tuft cell-like signature is highly prevalent in thymic squamous cell carcinoma and delineates new molecular subsets among the major lung cancer histotypes.
    J Thorac Oncol. 2021 Feb 17. pii: S1556-0864(21)01708.
    PubMed     Abstract available


  217. BLACKHALL F, Jao K, Greillier L, Cho BC, et al
    Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High Small Cell Lung Cancer: Results from the Phase 3 TAHOE Study.
    J Thorac Oncol. 2021 Feb 16. pii: S1556-0864(21)01709.
    PubMed     Abstract available


  218. OSAROGIAGBON RU, Smeltzer MP, Faris NR, Ray MA, et al
    Outcomes Following Use of a Lymph Node Collection Kit for Lung Cancer Surgery: A Pragmatic, Population-Based, Multi-Institutional, Staggered Implementation Study.
    J Thorac Oncol. 2021 Feb 16. pii: S1556-0864(21)01658.
    PubMed     Abstract available


  219. YUN JK, Lee GD, Choi S, Kim YH, et al
    A Validation Study on the Recommended Change in Residual Tumor Descriptors Proposed by the International Association for the Study of Lung Cancer for Patients with pN2 Non-small Cell Lung Cancer.
    J Thorac Oncol. 2021 Feb 16. pii: S1556-0864(21)01668.
    PubMed     Abstract available


  220. ZHANG Y, Luo G, Etxeberria J, Hao Y, et al
    Global patterns and trends in lung cancer incidence: a population-based study.
    J Thorac Oncol. 2021 Feb 16. pii: S1556-0864(21)01700.
    PubMed     Abstract available


  221. YANG Y, Huang J, Wang T, Zhou J, et al
    Decoding the Evolutionary Response to Ensartinib in ALK-Positive Non-Small-Cell Lung Cancer Patients by Dynamic Circulating Tumor DNA Sequencing.
    J Thorac Oncol. 2021 Feb 12. pii: S1556-0864(21)01662.
    PubMed     Abstract available


  222. RAY MA, Fehnel C, Akinbobola O, Faris NR, et al
    Comparative Effectiveness of a Lymph Node Collection kit Versus 'Heightened Awareness' on Lung Cancer Surgery Quality and Outcomes.
    J Thorac Oncol. 2021 Feb 12. pii: S1556-0864(21)01665.
    PubMed     Abstract available


  223. RADONIC T, Geurts-Giele WRR, Samsom KG, Roemen GMJM, et al
    RET FISH analysis is a sensitive but highly unspecific screening method for RET fusions in lung cancer.
    J Thorac Oncol. 2021 Feb 12. pii: S1556-0864(21)01666.
    PubMed     Abstract available


  224. AREDO JV, Mambetsariev I, Hellyer JA, Amini A, et al
    Durvalumab for Stage III EGFR-Mutated Non-Small Cell Lung Cancer After Definitive Chemoradiotherapy.
    J Thorac Oncol. 2021 Feb 12. pii: S1556-0864(21)01702.
    PubMed     Abstract available


  225. HENDERSON LM, Durham DD, Tammemagi MC, Benefield T, et al
    Lung Cancer Screening with Low Dose Computed Tomography in Patients With and Without Prior History of Cancer in the National Lung Screening Trial.
    J Thorac Oncol. 2021 Feb 10. pii: S1556-0864(21)01703.
    PubMed     Abstract available


  226. YE L, Creaney J, Redwood A, Robinson B, et al
    The current lung cancer neoantigen landscape and implications for therapy.
    J Thorac Oncol. 2021 Feb 10. pii: S1556-0864(21)01698.
    PubMed     Abstract available


  227. ILIE M, MaziEres J, Chamorey E, Heeke S, et al
    Prospective multi-center validation of the detection of ALK rearrangements of circulating tumor cells for non-invasive longitudinal management of patients with advanced non-small cell lung cancer.
    J Thorac Oncol. 2021 Feb 3. pii: S1556-0864(21)01664.
    PubMed     Abstract available


  228. DAGOGO-JACK I, Moonsamy P, Gainor JF, Lennerz JK, et al
    A Phase II Study of Capmatinib in Patients with MET-Altered Lung Cancer Previously Treated with a MET Inhibitor.
    J Thorac Oncol. 2021 Feb 2. pii: S1556-0864(21)01650.
    PubMed     Abstract available


  229. BARTLETT EC, Silva M, Callister ME, Devaraj A, et al
    False negative results in lung cancer screening - Evidence and Controversies.
    J Thorac Oncol. 2021 Feb 2. pii: S1556-0864(21)01652.
    PubMed     Abstract available


  230. JOSEPH N, Choudhury A
    Dosimetric Predictors of Radiotherapy-Induced Lymphocytopenia in Lung Cancer.
    J Thorac Oncol. 2021;16:e11-e12.
    PubMed    


  231. LEIGHL NB
    Meeting Immunotherapy Resistance in Lung Cancer.
    J Thorac Oncol. 2021;16:187-190.
    PubMed    


  232. LEE J, Ahn MJ
    A Response to the Letter to the Editor: Osimertinib Leads the Way Towards Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases.
    J Thorac Oncol. 2021;16:e14.
    PubMed    


  233. ZHENG MM, Li YS, Sun H, Wu YL, et al
    Osimertinib Leads the Way Toward Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases.
    J Thorac Oncol. 2021;16:e12-e14.
    PubMed    


  234. TSUI DCC, Camidge DR
    Molecular Profiling of the Cerebrospinal Fluid in Leptomeningeal NSCLC: The Shape of Things to Come?
    J Thorac Oncol. 2021;16:194-196.
    PubMed    


  235. SEQUIST LV, Skates SJ, Haas W
    A New Era of Protein-Based Assays for Cancer Early Detection.
    J Thorac Oncol. 2021;16:191-193.
    PubMed    


  236. FERRARA R, Campochiaro C, Garassino MC
    Shifting From a "One Size Fits All" to a Tailored Approach for Immune-Related Adverse Events.
    J Thorac Oncol. 2021;16:183-186.
    PubMed    


  237. PADDA SK, Reckamp KL
    Combination of Immunotherapy and Antiangiogenic Therapy in Cancer-a Rational Approach.
    J Thorac Oncol. 2021;16:178-182.
    PubMed    


  238. MOK T, Peters S, Camidge DR, Noe J, et al
    Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study.
    J Thorac Oncol. 2021;16:259-268.
    PubMed     Abstract available


  239. LI B, Zhang Y, Miao L, Ma L, et al
    Esophagectomy With Three-Field Versus Two-Field Lymphadenectomy for Middle and Lower Thoracic Esophageal Cancer: Long-Term Outcomes of a Randomized Clinical Trial.
    J Thorac Oncol. 2021;16:310-317.
    PubMed     Abstract available


  240. BANFILL K, Giuliani M, Aznar M, Franks K, et al
    Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions.
    J Thorac Oncol. 2021;16:216-227.
    PubMed     Abstract available


  241. GJYSHI O, Xu T, Elhammali A, Boyce-Fappiano D, et al
    Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC.
    J Thorac Oncol. 2021;16:269-277.
    PubMed     Abstract available


  242. PETERS S, Felip E, Dafni U, Tufman A, et al
    Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology P
    J Thorac Oncol. 2021;16:278-288.
    PubMed     Abstract available


  243. JIANG T, Fang Z, Tang S, Cheng R, et al
    Mutational Landscape and Evolutionary Pattern of Liver and Brain Metastasis in Lung Adenocarcinoma.
    J Thorac Oncol. 2021;16:237-249.
    PubMed     Abstract available


  244. OSTRIN EJ, Bantis LE, Wilson DO, Patel N, et al
    Contribution of a Blood-Based Protein Biomarker Panel to the Classification of Indeterminate Pulmonary Nodules.
    J Thorac Oncol. 2021;16:228-236.
    PubMed     Abstract available


  245. LE X, Nilsson M, Goldman J, Reck M, et al
    Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:205-215.
    PubMed     Abstract available


  246. MOI L, Bouchaab H, Mederos N, Nguyen-Ngoc T, et al
    Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis.
    J Thorac Oncol. 2021;16:318-326.
    PubMed     Abstract available


    January 2021
  247. RECK M, Ciuleanu TE, Lee JS, Schenker M, et al
    First-Line Nivolumab Plus Ipilimumab vs Chemotherapy in Advanced Non-Small Cell Lung Cancer With Tumor PD-L1 >/= 1%: Patient-Reported Outcomes From CheckMate 227 Part 1.
    J Thorac Oncol. 2021 Jan 21. pii: S1556-0864(21)00041.
    PubMed     Abstract available


  248. CARBONE M, Lednicky J, Xiao SY, Venditti M, et al
    Coronavirus Infectious Disease Epidemic (COVID-19): where we are, what can be done and hope for.
    J Thorac Oncol. 2021 Jan 7. pii: S1556-0864(20)31140.
    PubMed     Abstract available


  249. LI L, Ling Y, Guo C, Guo L, et al
    Necrosis Is Not the Main Part of Immune-Related Pathologic Response to Neoadjuvant Immunotherapy in Squamous Cell Lung Cancer.
    J Thorac Oncol. 2021;16:e7-e9.
    PubMed    


  250. PUJOL JL, Thomas PA, Giraud P, Denis MG, et al
    Lung Cancer in France.
    J Thorac Oncol. 2021;16:21-29.
    PubMed    


  251. HAMANN HA, Williamson TJ, Studts JL, Ostroff JS, et al
    Lung Cancer Stigma Then and Now: Continued Challenges Amid a Landscape of Progress.
    J Thorac Oncol. 2021;16:17-20.
    PubMed    


  252. SHOJAEE S, Nana-Sinkam P
    One Metformin a Day, Keeps Lung Cancer Away! Or Does It?
    J Thorac Oncol. 2021;16:11-13.
    PubMed    


  253. TRAVIS WD, Dacic S, Sholl LM, Wistuba II, et al
    Pathologic Assessment of Lung Squamous Cell Carcinoma After Neoadjuvant Immunotherapy.
    J Thorac Oncol. 2021;16:e9-e10.
    PubMed    


  254. CALLSTROM MR, de Baere T
    Response to Is Cryoablation Really Safe and Efficacious: Analyzing Results Within SOLSTICE Trial.
    J Thorac Oncol. 2021;16:e6-e7.
    PubMed    


  255. SHARMA A, Kamal VK
    Is Cryoablation Really Safe and Efficacious? Analyzing Results From the SOLSTICE Trial.
    J Thorac Oncol. 2021;16:e5.
    PubMed    


  256. BAIRD AM, Finn SP, Gray SG, Sheils O, et al
    Epigenetic Modifier UHRF1 May Be a Potential Target in Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2021;16:14-16.
    PubMed    


  257. LEE JJ, Yin G
    Principles and Reporting of Bayesian Trials.
    J Thorac Oncol. 2021;16:30-36.
    PubMed     Abstract available


  258. SANDS J, Tammemagi MC, Couraud S, Baldwin DR, et al
    Lung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation.
    J Thorac Oncol. 2021;16:37-53.
    PubMed     Abstract available


  259. SATO H, Offin M, Kubota D, Yu HA, et al
    Allele-Specific Role of ERBB2 in the Oncogenic Function of EGFR L861Q in EGFR-Mutant Lung Cancers.
    J Thorac Oncol. 2021;16:113-126.
    PubMed     Abstract available


  260. DIMOU A, Grewe P, Sidney J, Sette A, et al
    HLA Class I Binding of Mutant EGFR Peptides in NSCLC Is Associated With Improved Survival.
    J Thorac Oncol. 2021;16:104-112.
    PubMed     Abstract available


  261. REARDON ES, Shukla V, Xi S, Gara SK, et al
    UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2021;16:89-103.
    PubMed     Abstract available


    December 2020
  262. NISHIO M, Barlesi F, West H, Ball S, et al
    Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial.
    J Thorac Oncol. 2020 Dec 14. pii: S1556-0864(20)31100.
    PubMed     Abstract available


  263. CHU T, Zhong R, Zhong H, Zhang B, et al
    Phase Ib Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients with Advanced Non-small Cell Lung Cancer.
    J Thorac Oncol. 2020 Dec 14. pii: S1556-0864(20)31101.
    PubMed     Abstract available


  264. KRON A, Scheffler M, Heydt C, Ruge L, et al
    Genetic Heterogeneity of MET-aberrant Non-Small Cell Lung Cancer and its Impact on the Outcome of Immunotherapy.
    J Thorac Oncol. 2020 Dec 9. pii: S1556-0864(20)31091.
    PubMed     Abstract available


  265. PAN D, Hu AY, Antonia SJ, Li CY, et al
    A Gene Mutation Signature Predicting Immunotherapy Benefits in Non-Small Cell Lung Cancer Patients.
    J Thorac Oncol. 2020 Dec 8. pii: S1556-0864(20)31096.
    PubMed     Abstract available


  266. HELLYER JA, Padda SK, Diehn M, Wakelee HA, et al
    Clinical implications of KEAP1-NFE2L2 mutations in non-small cell lung cancer.
    J Thorac Oncol. 2020 Dec 8. pii: S1556-0864(20)31089.
    PubMed     Abstract available


  267. SCOTT JG, Sedor G, Scarborough JA, Kattan MW, et al
    Personalizing Radiotherapy Prescription Dose Using Genomic Markers of Radiosensitivity and Normal Tissue Toxicity in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2020 Dec 7. pii: S1556-0864(20)31046.
    PubMed     Abstract available


  268. JOHN T, Cooper WA, Wright G, Siva S, et al
    Lung Cancer in Australia.
    J Thorac Oncol. 2020;15:1809-1814.
    PubMed    


  269. ROSSI G, Caruso D, Stella F, Davoli F, et al
    Histologic Confounding Findings in Coronavirus disease 2019 (COVID-19) Pathology.
    J Thorac Oncol. 2020;15:e192-e193.
    PubMed    


  270. CAI Y, Kuang D, Zhang N
    Response to Letter to the Editor.
    J Thorac Oncol. 2020;15:e193-e194.
    PubMed    


  271. YANG Y, Zhou H, Zhang L
    Response to Letter to the Editor: Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: A Randomized, Double-Blind, Phase 3 Study (ORIENT-11).
    J Thorac Oncol. 2020;15:e191-e192.
    PubMed    


  272. CUI L, Zhao N, Zhang Z, Jiao X, et al
    Comparing Immunotherapies in Combination With Chemotherapy for Previously Untreated Advanced Nonsquamous NSCLC.
    J Thorac Oncol. 2020;15:e189-e191.
    PubMed    


  273. CASO R, Jones DR
    Response to the Letter to the Editor: Clinical and Pathologic Implications of Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma.
    J Thorac Oncol. 2020;15:e188-e189.
    PubMed    


  274. XU X, Mao Y, Ding Q, Chen Y, et al
    Clinical and Pathologic Implications of Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma.
    J Thorac Oncol. 2020;15:e187-e188.
    PubMed    


  275. YATABE Y
    Reassessing the SCLC Subtypes.
    J Thorac Oncol. 2020;15:1819-1822.
    PubMed    


  276. PUNEKAR SR, Shum E
    Expanding the Role of Immunotherapy to Limited-Stage SCLC.
    J Thorac Oncol. 2020;15:1806-1808.
    PubMed    


  277. AHN BC, Zhu VW, Lim SM
    The Next Target for NSCLC: Let It Be "RET".
    J Thorac Oncol. 2020;15:1803-1805.
    PubMed    


  278. MAMDANI H, Schwartz AG
    Genomic Characterization of NSCLC in African Americans: A Step Toward "Race-Aware" Precision Medicine.
    J Thorac Oncol. 2020;15:1800-1802.
    PubMed    


  279. ARAUZ RF, Byun JS, Tandon M, Sinha S, et al
    Whole-Exome Profiling of NSCLC Among African Americans.
    J Thorac Oncol. 2020;15:1880-1892.
    PubMed     Abstract available


  280. YANG JC, Camidge DR, Yang CT, Zhou J, et al
    Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial.
    J Thorac Oncol. 2020;15:1907-1918.
    PubMed     Abstract available


  281. DUAN J, Xu J, Wang Z, Bai H, et al
    Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment.
    J Thorac Oncol. 2020;15:1857-1870.
    PubMed     Abstract available


  282. ESAI SELVAN M, Zauderer MG, Rudin CM, Jones S, et al
    Inherited Rare, Deleterious Variants in ATM Increase Lung Adenocarcinoma Risk.
    J Thorac Oncol. 2020;15:1871-1879.
    PubMed     Abstract available


  283. CASO R, Sanchez-Vega F, Tan KS, Mastrogiacomo B, et al
    The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma.
    J Thorac Oncol. 2020;15:1844-1856.
    PubMed     Abstract available


    November 2020
  284. OWONIKOKO TK, Dwivedi B, Chen Z, Zhang C, et al
    YAP1 Expression in Small Cell Lung Cancer Defines a Distinct Subtype with T-cell Inflamed Phenotype.
    J Thorac Oncol. 2020 Nov 25. pii: S1556-0864(20)31028.
    PubMed     Abstract available


  285. NISHIO M, Yoshida T, Kumagai T, Hida T, et al
    Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial.
    J Thorac Oncol. 2020 Nov 25. pii: S1556-0864(20)31026.
    PubMed     Abstract available


  286. SPIGEL D, Jotte R, Nemunaitis J, Shum M, et al
    Brief Report: Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination with Pegilodecakin in Patients with Metastatic Non-Small-Cell Lung Cancer (CYPRESS-1 and CYPRESS-2).
    J Thorac Oncol. 2020 Nov 6. pii: S1556-0864(20)30805.
    PubMed     Abstract available


  287. FURUTA H, Araki M, Masago K, Sagae Y, et al
    Novel resistance mechanisms including L1196Q, P1094H, and R1248_D1249insertion in three patients with non-small-cell lung cancer following ALK tyrosine kinase inhibitor treatment.
    J Thorac Oncol. 2020 Nov 6. pii: S1556-0864(20)30803.
    PubMed     Abstract available


  288. CHUN SG, Simone CB 2nd, Amini A, Chetty IJ, et al
    American Radium Society Appropriate Use Criteria: Radiation Therapy for Limited-stage Small Cell Lung Cancer 2020.
    J Thorac Oncol. 2020 Nov 6. pii: S1556-0864(20)30846.
    PubMed     Abstract available


  289. FAN Y, Zhao J, Wang Q, Huang D, et al
    Camrelizumab Plus Apatinib in Extensive-Stage Small-Cell Lung Cancer (PASSION): A Multicenter, Two-Stage, Phase 2 Trial.
    J Thorac Oncol. 2020 Nov 6. pii: S1556-0864(20)30806.
    PubMed     Abstract available


  290. MAZIERES J, Rittmeyer A, Gadgeel S, Hida T, et al
    Atezolizumab vs Docetaxel in Pretreated Patients with Non-Small Cell Lung Cancer: Final Results From the Randomized Phase II POPLAR and Phase III OAK Clinical Trials.
    J Thorac Oncol. 2020 Nov 6. pii: S1556-0864(20)30802.
    PubMed     Abstract available


  291. OSAROGIAGBON RU, Ray MA, Faris NR, Smeltzer MP, et al
    Response to Clinical Thoughts on Mediastinal Node Management in Early-Stage Lung Cancer.
    J Thorac Oncol. 2020;15:e185-e186.
    PubMed    


  292. CHEN D, Mao Y, Chen Y, Chen C, et al
    Clinical Thoughts on Mediastinal Node Management in Early-Stage Lung Cancer.
    J Thorac Oncol. 2020;15:e183-e184.
    PubMed    


  293. REUNGWETWATTANA T, Oranratnachai S, Puataweepong P, Tangsujaritvijit V, et al
    Lung Cancer in Thailand.
    J Thorac Oncol. 2020;15:1714-1721.
    PubMed    


  294. TANNER NT, Rivera MP
    Improving Inequities in Lung Cancer Screening: Risk Prediction Models and the Potential to Achieve a Great Equalizer Effect.
    J Thorac Oncol. 2020;15:1711-1713.
    PubMed    


  295. ADJEI AA
    A Call to Arms: Reducing Disparities in Lung Cancer Care Worldwide.
    J Thorac Oncol. 2020;15:1700-1702.
    PubMed    


  296. BAKHRIBAH H, Alfayea T
    Immunotherapy and Coronavirus Disease 2019: Challenges and Possibilities.
    J Thorac Oncol. 2020;15:1709-1710.
    PubMed    


  297. LU S, Li Z
    Adverse Effects of Combined Tyrosine Kinase Inhibitors.
    J Thorac Oncol. 2020;15:e182-e183.
    PubMed    


  298. LI Z, Deng J, Yan F, Ma Y, et al
    Letter to the Editor About the Adverse Effect of Combined Tyrosine Kinase Inhibitors.
    J Thorac Oncol. 2020;15:e181-e182.
    PubMed    


  299. HEGDE A, Velcheti V
    Osimertinib for Leptomeningeal Disease in EGFR-Mutated NSCLC.
    J Thorac Oncol. 2020;15:1705-1708.
    PubMed    


  300. ALEXANDER M, Wrangle J
    Can We MIRror the Efficacy of Immune Checkpoints With miRNAs?
    J Thorac Oncol. 2020;15:1703-1704.
    PubMed    


  301. RICE SJ, Hyland V, Behera M, Ramalingam SS, et al
    Guidance on the Clinical Management of Electronic Cigarette or Vaping-Associated Lung Injury.
    J Thorac Oncol. 2020;15:1727-1737.
    PubMed     Abstract available


  302. OU FS, Le-Rademacher JG, Ballman KV, Adjei AA, et al
    Guidelines for Statistical Reporting in Medical Journals.
    J Thorac Oncol. 2020;15:1722-1726.
    PubMed     Abstract available


    October 2020
  303. ZHENG MM, Li YS, Tu HY, Jiang BY, et al
    Genotyping of cerebrospinal fluid associated with osimertinib response and resistance for leptomeningeal metastases in EGFR-mutated non-small cell lung cancer.
    J Thorac Oncol. 2020 Oct 26. pii: S1556-0864(20)30816.
    PubMed     Abstract available


  304. REMON J, Reguart N, Garcia-Campelo R, Conde E, et al
    Lung Cancer in Spain.
    J Thorac Oncol. 2020 Oct 24. pii: S1556-0864(20)30812.
    PubMed    


  305. GAUDREAU PO, Negrao MV, Mitchell KG, Reuben A, et al
    Neoadjuvant Chemotherapy Increases Cytotoxic T cell, Tissue Resident Memory T cell and B Cell Infiltration in Resectable Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2020 Oct 20. pii: S1556-0864(20)30813.
    PubMed     Abstract available


  306. HERBST RS, Arkenau HT, Bendell J, Arrowsmith E, et al
    Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2020 Oct 14. pii: S1556-0864(20)30809.
    PubMed     Abstract available


  307. RAMI-PORTA R, Wittekind C, Goldstraw P
    Complete Resection in Lung Cancer Surgery: From Definition to Validation and Beyond.
    J Thorac Oncol. 2020 Oct 13. pii: S1556-0864(20)30727.
    PubMed    


  308. STINCHCOMBE TE, Doebele RC, Wang X, Gerber DE, et al
    Brief report: Preliminary clinical and molecular analysis results from a single arm phase 2 trial of brigatinib in patients with disease progression after next-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors in advanced ALK + no
    J Thorac Oncol. 2020 Oct 8. pii: S1556-0864(20)30764.
    PubMed     Abstract available


  309. KIDANE B, Levin DP
    Identification and Resolution of Asymptomatic COVID-19 Pneumonitis and Colitis: Serial Assessment of Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography for Evaluation of Lung Cancer.
    J Thorac Oncol. 2020 Oct 5. pii: S1556-0864(20)30725.
    PubMed    


  310. SEITLINGER J, Banga Nkomo D, Streit A, Stasiak F, et al
    Letter to the Editor Concerning the Article From Cai et al. Focusing on Coronavirus Disease 2019 Impact on Lung Cancer Resection, Published in June 2020.
    J Thorac Oncol. 2020;15:e172-e173.
    PubMed    


  311. GAO S, Li N, Wang S, Zhang F, et al
    Lung Cancer in People's Republic of China.
    J Thorac Oncol. 2020;15:1567-1576.
    PubMed    


  312. LIM E
    What Is the Optimum Lymph Node Management in Patients Undergoing Surgery for Lung Cancer?
    J Thorac Oncol. 2020;15:1565-1566.
    PubMed    


  313. SCHILD SE
    Optimizing the Radiotherapy of Lung Cancer.
    J Thorac Oncol. 2020;15:1559-1560.
    PubMed    


  314. LAM VK, Forde PM
    Another Brick in the Wall: Sintilimab Plus Chemotherapy in Advanced Lung Cancer.
    J Thorac Oncol. 2020;15:1556-1558.
    PubMed    


  315. RIGNEY M, Rapsomaniki E, Carter-Harris L, King JC, et al
    Brief Report: Ten Year Cross-sectional Analysis of Public, Oncologist, and Patient Attitudes About Lung Cancer and Associated Stigma.
    J Thorac Oncol. 2020 Oct 1. pii: S1556-0864(20)30757.
    PubMed     Abstract available


  316. HIGGINS KA, Simone CB 2nd, Amini A, Chetty IJ, et al
    American Radium Society , Appropriate Use Criteria on Radiation Therapy for Extensive-stage Small Cell Lung Cancer.
    J Thorac Oncol. 2020 Oct 1. pii: S1556-0864(20)30759.
    PubMed     Abstract available


  317. BAINE MK, Hsieh MS, Lai WV, Egger JV, et al
    Small Cell Lung Carcinoma Subtypes Defined by ASCL1, NEUROD1, POU2F3 and YAP1: Comprehensive Immunohistochemical and Histopathologic Characterization.
    J Thorac Oncol. 2020 Oct 1. pii: S1556-0864(20)30755.
    PubMed     Abstract available


  318. KUNIMASA K, Honma K, Matsumoto M, Nishino K, et al
    Dermatopathic Lymphadenopathy Mimicking Disease Progression During Osimertinib Treatment.
    J Thorac Oncol. 2020;15:e178-e180.
    PubMed    


  319. MATSUDA K, Kashima J, Yatabe Y
    The Isoform Matters in NUT Carcinoma: A Diagnostic Pitfall of p40 Immunohistochemistry.
    J Thorac Oncol. 2020;15:e176-e178.
    PubMed    


  320. DAGOGO-JACK I
    Durable Response to Dabrafenib Combined With Trametinib in a Patient With NSCLC Harboring a BRAF G469A Mutation.
    J Thorac Oncol. 2020;15:e174-e176.
    PubMed    


  321. CAI Y, Gao Y, Zhang N
    Response to Letter to the Editor.
    J Thorac Oncol. 2020;15:e173-e174.
    PubMed    


  322. PIGNATARO D, Bertaglia V, Bironzo P, Olmetto E, et al
    Oligoprogressive Disease With SCLC Transformation in EGFR-Mutated NSCLC: How Biology Knowledge Can Change the Game Rules.
    J Thorac Oncol. 2020;15:e170-e172.
    PubMed    


  323. HASSAN R, Miettinen M
    Response to Letter to Editor by Cornelissen et al.
    J Thorac Oncol. 2020;15:e169-e170.
    PubMed    


  324. CORNELISSEN R, Dubbink HJ, von der Thusen JH
    ALK in Mesothelioma: To FISH or Not to FISH?
    J Thorac Oncol. 2020;15:e168-e169.
    PubMed    


  325. MORENO AC, Lin SH
    Authors' Reply to Yajing Du's Letter to the Editor on "Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients With Early-Stage NSCLC".
    J Thorac Oncol. 2020;15:e166-e168.
    PubMed    


  326. DU Y, Zhan C, Li M, Qiao T, et al
    Promising Stereotactic Body Radiotherapy in NSCLC.
    J Thorac Oncol. 2020;15:e165-e166.
    PubMed    


  327. COLEMAN N, Woolf D, Welsh L, McDonald F, et al
    EGFR Exon 20 Insertion (A763_Y764insFQEA) Mutant NSCLC Is Not Identified by Roche Cobas Version 2 Tissue Testing but Has Durable Intracranial and Extracranial Response to Osimertinib.
    J Thorac Oncol. 2020;15:e162-e165.
    PubMed    


  328. WANG YY, Tian XC, Zhu L, Bai XH, et al
    Concomitant Radiation Recall Dermatitis and Radiation Recall Pneumonitis Induced by Pembrolizumab.
    J Thorac Oncol. 2020;15:e160-e162.
    PubMed    


  329. LI M, Xu Z, Zhan C, Wang Q, et al
    A Few Clouds Over the Eighth Edition T Categorization System.
    J Thorac Oncol. 2020;15:e159-e160.
    PubMed    


  330. CHU QSC
    How Is Receptor Activator of Nuclear Factor-kappabeta/Receptor Activator of Nuclear Factor-kappabeta Ligand Targeting Ranked as an Immuno-Oncology Target for NSCLC: a Pathway Unclear as yet?
    J Thorac Oncol. 2020;15:1561-1564.
    PubMed    


  331. SINGH S, Bergsland EK, Card CM, Hope TA, et al
    Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Updat
    J Thorac Oncol. 2020;15:1577-1598.
    PubMed     Abstract available


  332. WANG X, Palaskas NL, Yusuf SW, Abe JI, et al
    Incidence and Onset of Severe Cardiac Events After Radiotherapy for Esophageal Cancer.
    J Thorac Oncol. 2020;15:1682-1690.
    PubMed     Abstract available


  333. PETERS S, Danson S, Hasan B, Dafni U, et al
    A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLE
    J Thorac Oncol. 2020;15:1647-1656.
    PubMed     Abstract available


  334. MOREIRA AL, Ocampo PSS, Xia Y, Zhong H, et al
    A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee.
    J Thorac Oncol. 2020;15:1599-1610.
    PubMed     Abstract available


  335. NEGRAO MV, Raymond VM, Lanman RB, Robichaux JP, et al
    Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations.
    J Thorac Oncol. 2020;15:1611-1623.
    PubMed     Abstract available


    September 2020
  336. AWAD MM, Gadgeel SM, Borghaei H, Patnaik A, et al
    Brief Report: Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2020 Sep 28. pii: S1556-0864(20)30761.
    PubMed     Abstract available


  337. KANG J, Jeong SM, Shin DW, Cho M, et al
    Associations of aspirin, statins, and metformin with lung cancer risk and related mortality: time-dependent analysis of population-based nationally representative data.
    J Thorac Oncol. 2020 Sep 12. pii: S1556-0864(20)30712.
    PubMed     Abstract available


  338. GEMMA A, Kusumoto M, Sakai F, Endo M, et al
    Real-world evaluation of factors for interstitial lung disease incidence and radiologic characteristics in patients with epidermal growth factor receptor T790M-positive non-small cell lung cancer treated with osimertinib in Japan.
    J Thorac Oncol. 2020 Sep 11. pii: S1556-0864(20)30717.
    PubMed     Abstract available


  339. WELSH JW, Heymach JV, Guo C, Menon H, et al
    Phase I/II Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage Small Cell Lung Cancer.
    J Thorac Oncol. 2020 Sep 8. pii: S1556-0864(20)30713.
    PubMed     Abstract available


  340. BRAUN M, Fuchs V, Kian W, Roisman L, et al
    Nivolumab Induced Hepatocanalicular Cholestasis and Liver Rejection in a Patient With Lung Cancer and Liver Transplant.
    J Thorac Oncol. 2020;15:e149-e150.
    PubMed    


  341. GEDVILAITE V, Danila E, Cicenas S, Smailyte G, et al
    Lung Cancer in Lithuania.
    J Thorac Oncol. 2020;15:1401-1405.
    PubMed    


  342. AHN MJ
    Molecular Testing in Lung Cancer: Still Big Gap in Implementation for Real-World Use.
    J Thorac Oncol. 2020;15:1399-1400.
    PubMed    


  343. ZHOU F, Zhou C
    Treatment Algorithm for Advanced ALK-Rearranged NSCLC: Reply.
    J Thorac Oncol. 2020;15:e157-e158.
    PubMed    


  344. URBANSKA EM, Sorensen JB, Santoni-Rugiu E
    Treatment Algorithm for Advanced ALK-Rearranged NSCLC.
    J Thorac Oncol. 2020;15:e156-e157.
    PubMed    


  345. HAURA EB, Hicks JK, Boyle TA
    Erdafitinib Overcomes FGFR3-TACC3-Mediated Resistance to Osimertinib.
    J Thorac Oncol. 2020;15:e154-e156.
    PubMed    


  346. ZHENG J, Sun W, Chen W, Zhou J, et al
    Sustained Response to Crizotinib After Resistance to First-Line Alectinib Treatment in Two Patients With ALK-Rearranged NSCLC.
    J Thorac Oncol. 2020;15:e150-e153.
    PubMed    


  347. OKUDA K, Nakanishi R
    Circulating Cancer-Associated Cells for the Early Detection and Decision-Making Concerning Effective Therapeutic Strategies for NSCLC.
    J Thorac Oncol. 2020;15:1397-1398.
    PubMed    


  348. LYCAN TW JR, Petty WJ
    Adverse Event Reporting at Professional Conferences: We Need Better Standards and Bigger Posters.
    J Thorac Oncol. 2020;15:1394-1396.
    PubMed    


  349. GOTO Y
    Current Understanding and Biomarker Application of Programmed Death-Ligand 1 Expression in Tumors.
    J Thorac Oncol. 2020;15:1392-1393.
    PubMed    


  350. ADDEO A, Banna LG, Friedlaender A
    Filtering Data About Treatment-Induced Renal Injury: From Biology to Practice.
    J Thorac Oncol. 2020;15:1389-1391.
    PubMed    


  351. KERN JA, Kim J, Foster DG, Mishra R, et al
    Role of mTOR As an Essential Kinase in SCLC.
    J Thorac Oncol. 2020;15:1522-1534.
    PubMed     Abstract available


  352. DAHLBERG SE, Korn EL, Le-Rademacher J, Mandrekar SJ, et al
    Clinical Versus Statistical Significance in Studies of Thoracic Malignancies.
    J Thorac Oncol. 2020;15:1406-1408.
    PubMed    


  353. OYAMA T, Goto T, Amemiya K, Hirotsu Y, et al
    Squamous Cell Carcinoma of the Lung With Micropapillary Pattern.
    J Thorac Oncol. 2020;15:1541-1544.
    PubMed    


  354. SHOLL LM, Hirsch FR, Hwang D, Botling J, et al
    The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.
    J Thorac Oncol. 2020;15:1409-1424.
    PubMed     Abstract available


  355. DUMOULIN DW, Visser S, Cornelissen R, van Gelder T, et al
    Renal Toxicity From Pemetrexed and Pembrolizumab in the Era of Combination Therapy in Patients With Metastatic Nonsquamous Cell NSCLC.
    J Thorac Oncol. 2020;15:1472-1483.
    PubMed     Abstract available


  356. ZHU VW, Lin YT, Kim DW, Loong HH, et al
    An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC.
    J Thorac Oncol. 2020;15:1484-1496.
    PubMed     Abstract available


    August 2020
  357. TAN AC, Seet AOL, Lai GGY, Lim TH, et al
    Molecular characterisation and clinical outcomes in RET rearranged non-small cell lung cancer (NSCLC).
    J Thorac Oncol. 2020 Aug 28. pii: S1556-0864(20)30671.
    PubMed     Abstract available


  358. CALABRESE F, Fortarezza F, Giraudo C, Pezzuto F, et al
    Two sorts of microthrombi in a COVID-19 patient with lung cancer.
    J Thorac Oncol. 2020 Aug 28. pii: S1556-0864(20)30668.
    PubMed    


  359. IKEDA S, Kato T, Kenmotsu H, Ogura T, et al
    A phase II study of atezolizumab for pretreated non-small cell lung cancer with idiopathic interstitial pneumonias.
    J Thorac Oncol. 2020 Aug 25. pii: S1556-0864(20)30678.
    PubMed     Abstract available


  360. PASQUINELLI MM, Tammemagi MC, Kovitz KL, Durham ML, et al
    Risk Prediction Model versus United States Preventive Services Task Force Lung Cancer Screening Eligibility Criteria - Reducing Race Disparities.
    J Thorac Oncol. 2020 Aug 17. pii: S1556-0864(20)30638.
    PubMed     Abstract available


  361. ADAMEK M, Biernat W, Chorostowska-Wynimko J, Didkowska JA, et al
    Lung Cancer in Poland.
    J Thorac Oncol. 2020;15:1271-1276.
    PubMed    


  362. GU Z, Liu Y, Qiu B, Liu H, et al
    Risk Stratification Is Helpful in Designing Follow-Up Strategy and Future Studies on Adjuvant Therapies: Response to the External Validation on the Chinese Alliance for Research in Thymomas Predictive Model of Recurrence.
    J Thorac Oncol. 2020;15:e139-e141.
    PubMed    


  363. CHIAPPETTA M, Sperduti I, Lococo F, Margaritora S, et al
    Does Follow-Up Duration Affect the Effectiveness of a Predictive Nomogram Model for Thymic Malignancy Recurrences? Results From an External Validation.
    J Thorac Oncol. 2020;15:e137-e139.
    PubMed    


  364. DAGOGO-JACK I, Mino-Kenudson M
    Reply to the Letter to the Editor From Zhou et al.
    J Thorac Oncol. 2020;15:e136-e137.
    PubMed    


  365. ZHOU H, Shen J, Liu J, Fang W, et al
    Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Mutant NSCLC.
    J Thorac Oncol. 2020;15:e133-e136.
    PubMed    


  366. GENDARME S, Chouaid C
    Monitoring Subsolid Pulmonary Nodules in High-Risk Patients Is Even More Cost-Effective When Combined With a Stop-Smoking Program.
    J Thorac Oncol. 2020;15:1268-1270.
    PubMed    


  367. URUGA H, Mino-Kenudson M
    Is the Programmed Death-Ligand 1 73-10 Immunohistochemistry Assay Compatible With the 22C3 Assay?
    J Thorac Oncol. 2020;15:1265-1267.
    PubMed    


  368. PEROL M
    Multidisciplinary Approach of Immune Checkpoint Inhibitor-Related Pneumonitis: A Key to Address Knowledge and Management Gaps.
    J Thorac Oncol. 2020;15:1261-1264.
    PubMed    


  369. STINCHCOMBE TE
    IMpower 131: The Exception to the Rule.
    J Thorac Oncol. 2020;15:1258-1260.
    PubMed    


  370. KOKORIAN R, Grainville T, Robert L, Corre R, et al
    Coeliac-Like Disease Is a Rare Immune-Related Complication Induced by Nivolumab in NSCLC.
    J Thorac Oncol. 2020;15:e147-e148.
    PubMed    


  371. ARAKAWA S, Yoshida T, Nakayama Y, Motoi N, et al
    Small Cell Cancer Transformation of Lung Adenocarcinoma During Durvalumab Treatment After Chemoradiotherapy.
    J Thorac Oncol. 2020;15:e145-e146.
    PubMed    


  372. COLEMAN N, Yousaf N, Arkenau HT, Welsh L, et al
    Lorlatinib Salvages Central Nervous System-Only Relapse on Entrectinib in ROS1-Positive NSCLC.
    J Thorac Oncol. 2020;15:e142-e144.
    PubMed    


  373. ZHENG Q, Fang W, Huang Y, Gan J, et al
    Identification of a Novel KIF5B-RET, ABHD17C-RET Double-Fusion Variant in Lung Adenocarcinoma and Response to Cabozantinib.
    J Thorac Oncol. 2020;15:e132-e133.
    PubMed    


  374. MANDREKAR SJ, Le-Rademacher J, Adjei AA
    Introducing the Journal of Thoracic Oncology Statistical Series.
    J Thorac Oncol. 2020;15:1257.
    PubMed    


  375. AN MW, Duong Q, Le-Rademacher J, Mandrekar SJ, et al
    Principles of Good Clinical Trial Design.
    J Thorac Oncol. 2020;15:1277-1280.
    PubMed     Abstract available


  376. JEENE PM, Vermeulen BD, Rozema T, Braam PM, et al
    Short-Course External Beam Radiotherapy Versus Brachytherapy for Palliation of Dysphagia in Esophageal Cancer: A Matched Comparison of Two Prospective Trials.
    J Thorac Oncol. 2020;15:1361-1368.
    PubMed     Abstract available


  377. WANG Y, Yang N, Zhang Y, Li Li, et al
    Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy.
    J Thorac Oncol. 2020;15:1369-1375.
    PubMed     Abstract available


  378. KIM-WANNER SZ, Assenov Y, Nair MB, Weichenhan D, et al
    Genome-Wide DNA Methylation Profiling in Early Stage I Lung Adenocarcinoma Reveals Predictive Aberrant Methylation in the Promoter Region of the Long Noncoding RNA PLUT: An Exploratory Study.
    J Thorac Oncol. 2020;15:1338-1350.
    PubMed     Abstract available


  379. HAMMER MM, Palazzo LL, Paquette A, Eckel AL, et al
    Cost-Effectiveness of Follow-Up for Subsolid Pulmonary Nodules in High-Risk Patients.
    J Thorac Oncol. 2020;15:1298-1305.
    PubMed     Abstract available


    July 2020
  380. YANG Y, Wang Z, Fang J, Yu Q, et al
    Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3 study (ORIENT-11).
    J Thorac Oncol. 2020 Jul 31. pii: S1556-0864(20)30595.
    PubMed     Abstract available


  381. PEARSALL SM, Humphrey S, Revill M, Morgan D, et al
    The rare YAP1 subtype of Small Cell Lung Cancer revisited in a biobank of 39 Circulating Tumour Cell Patient Derived eXplant models (CDX): A brief report.
    J Thorac Oncol. 2020 Jul 25. pii: S1556-0864(20)30588.
    PubMed     Abstract available


  382. BUENO R, Richards WG, Harpole DH, Ballman KV, et al
    Multi-institutional prospective validation of prognostic mRNA signatures in early stage squamous lung cancer (Alliance).
    J Thorac Oncol. 2020 Jul 24. pii: S1556-0864(20)30558.
    PubMed     Abstract available


  383. ROLFO C, Cardona AF, Ruiz-Patino A, Ariza S, et al
    Atypical skin manifestations during immune checkpoint blockage in COVID19-infected lung cancer patients.
    J Thorac Oncol. 2020 Jul 9. pii: S1556-0864(20)30543.
    PubMed     Abstract available


  384. LEE J, La Choi Y, Han J, Park S, et al
    Osimertinib improves overall survival in EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastases regardless of T790M mutational status.
    J Thorac Oncol. 2020 Jul 8. pii: S1556-0864(20)30505.
    PubMed     Abstract available


  385. KILADZE I, Mariamidze E, Jeremic B
    Lung Cancer in Georgia.
    J Thorac Oncol. 2020;15:1113-1118.
    PubMed    


  386. SMELTZER MP, Osarogiagbon RU
    Out of the Darkness, Into Light: The Scientific Rigor of Lung Cancer Clinical Trials in the Age of Enlightenment.
    J Thorac Oncol. 2020;15:1110-1112.
    PubMed    


  387. LIN JJ, Solomon BJ
    Reply to "Emergence of High Level of MET Amplification During Treatment With Selpercatinib in KIF5B-RET NSCLC".
    J Thorac Oncol. 2020;15:e127-e128.
    PubMed    


  388. ZHU VW, Madison R, Schrock AB, Ou SI, et al
    Emergence of High Level of MET Amplification as Off-Target Resistance to Selpercatinib Treatment in KIF5B-RET NSCLC.
    J Thorac Oncol. 2020;15:e124-e127.
    PubMed    


  389. EMOTO K, Tan KS, Rekhtman N, Adusumilli PS, et al
    The Newly Described Filigree Pattern Is an Expansion of the Micropapillary Adenocarcinoma Concept Rather Than a Proposed New Subtype.
    J Thorac Oncol. 2020;15:e121-e124.
    PubMed    


  390. THUNNISSEN E, Flieder D
    Morphologic Logic: "Filigree" and "Classical" Micropapillary Pattern Are Orientation-Dependent Views of the Same Lesion.
    J Thorac Oncol. 2020;15:e120-e121.
    PubMed    


  391. TRAVIS WD, Aly RG, Rekhtman N, Tan KS, et al
    Spread Through Air Spaces Is Prognostic in Neuroendocrine Lung Tumors and Can Be Distinguished From Artifacts.
    J Thorac Oncol. 2020;15:e118-e120.
    PubMed    


  392. THUNNISSEN E, Marchevsky A, Rossi G, Russell PA, et al
    RE: Spread Through Air Spaces (STAS) is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung.
    J Thorac Oncol. 2020;15:e116-e117.
    PubMed    


  393. JEAN D, Delaunay T, Meiller C, Boisgerault N, et al
    Reply to: Oncolytic Viral Therapy for Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2020;15:e113-e116.
    PubMed    


  394. YANG H, Xu D, Gao Y, Schmid RA, et al
    Oncolytic Viral Therapy for Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2020;15:e111-e113.
    PubMed    


  395. GAUTSCHI O, Bubendorf L, Leyvraz S, Menon R, et al
    Challenges in the Diagnosis of NTRK Fusion-Positive Cancers.
    J Thorac Oncol. 2020;15:e108-e110.
    PubMed    


  396. SUTHERLAND KD, Vissers JHA
    Balancing the Count: Harmonizing Panel-Based Tumor Mutational Burden Assessment.
    J Thorac Oncol. 2020;15:1106-1109.
    PubMed    


  397. HSIAO SJ, Ou SI
    Is Retention of the 5' Nononcogenic ALK Fusion Variant a Novel Poor Prognostic Factor in ALK-Positive NSCLC?
    J Thorac Oncol. 2020;15:1103-1105.
    PubMed    


  398. LOONG HH, Li MSC, Tang GCH, Lau YM, et al
    Have We Revealed the Achilles' Heel of Brigatinib? Implications on Clinical Practice.
    J Thorac Oncol. 2020;15:1100-1102.
    PubMed    


  399. JETT JR, Kim ES
    Response to Letter to the Editor.
    J Thorac Oncol. 2020;15:e110-e111.
    PubMed    


  400. BARSKY AR, Kim MM, Williams GR, Lally BE, et al
    Proton-Beam Therapy: At the Heart of Cardiac Dose-Sparing in Mediastinal Radiotherapy for Thymic Carcinoma.
    J Thorac Oncol. 2020;15:1240-1242.
    PubMed    


  401. CALLSTROM MR, Woodrum DA, Nichols FC, Palussiere J, et al
    Multicenter Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation (SOLSTICE).
    J Thorac Oncol. 2020;15:1200-1209.
    PubMed     Abstract available


  402. STENZINGER A, Endris V, Budczies J, Merkelbach-Bruse S, et al
    Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study.
    J Thorac Oncol. 2020;15:1177-1189.
    PubMed     Abstract available


    June 2020
  403. PAZ-ARES L, Vicente D, Tafreshi A, Robinson A, et al
    A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407.
    J Thorac Oncol. 2020 Jun 26. pii: S1556-0864(20)30500.
    PubMed     Abstract available


  404. RAY MA, Smeltzer MP, Faris N, Osarogiagbon RU, et al
    Survival after mediastinal node dissection, systematic sampling or neither for early-stage non-small-cell lung cancer.
    J Thorac Oncol. 2020 Jun 20. pii: S1556-0864(20)30479.
    PubMed     Abstract available


  405. SHUKUYA T, Ghai V, Amann JM, Okimoto T, et al
    Circulating miRNAs and extracellular vesicle containing miRNAs as response biomarkers of anti PD-1/PD-L1 therapy in non-small-cell lung cancer.
    J Thorac Oncol. 2020 Jun 18. pii: S1556-0864(20)30467.
    PubMed     Abstract available


  406. ABRAVAN A, Faivre-Finn C, Kennedy J, McWilliam A, et al
    Radiotherapy-related lymphopenia affects overall survival in patients with lung cancer.
    J Thorac Oncol. 2020 Jun 14. pii: S1556-0864(20)30478.
    PubMed     Abstract available


  407. UPRETY D, Mandrekar SJ, Wigle D, Roden AC, et al
    Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer - Current Concepts and Future Approaches.
    J Thorac Oncol. 2020 Jun 6. pii: S1556-0864(20)30425.
    PubMed     Abstract available


  408. RUIZ R, Galvez-Nino M, Poquioma E, Limache-Garcia A, et al
    Lung Cancer in Peru.
    J Thorac Oncol. 2020;15:891-898.
    PubMed    


  409. WANG F, Adjei AA
    Does the Lung Cancer Field Need Another Third-Generation EGFR Tyrosine Kinase Inhibitor?
    J Thorac Oncol. 2020;15:881-883.
    PubMed    


  410. MCGINNIS GJ, Ning MS, Nitsch PL, O'Reilly MS, et al
    Rapid Detection of Asymptomatic Coronavirus Disease 2019 by Computed Tomography Image Guidance for Stereotactic Ablative Radiotherapy.
    J Thorac Oncol. 2020;15:1085-1087.
    PubMed    


  411. NICHOLSON AG, Sauter JL, Galateau-Salle F
    In Reply.
    J Thorac Oncol. 2020;15:e94-e95.
    PubMed    


  412. AUJAYEB A, Taylor L
    Is the Deciduoid Variant of Pleural Mesothelioma Significant?
    J Thorac Oncol. 2020;15:e94.
    PubMed    


  413. ARAI S, Yano S
    In Reply.
    J Thorac Oncol. 2020;15:e93.
    PubMed    


  414. CORTINOVIS D, Gemelli M, Cappuzzo F
    Alectinib Resistance Through Amphiregulin Overexpression: Is Osimertinib the Best Candidate?
    J Thorac Oncol. 2020;15:e92-e93.
    PubMed    


  415. HASSAN R, Sengupta M, Murai J, Pommier Y, et al
    Response to Letter to the Editor by Yang et al.
    J Thorac Oncol. 2020;15:e91.
    PubMed    


  416. YANG H, Xu D, Gao Y, Schmid RA, et al
    The Association of BAP1 Loss-of-Function With the Defect in Homologous Recombination Repair and Sensitivity to PARP-Targeted Therapy.
    J Thorac Oncol. 2020;15:e88-e90.
    PubMed    


  417. MAZZOTTA M, Marinelli D, Maugeri-Sacca M
    KEAP1-NFE2L2 Mutations in NSCLC: Increased Awareness Needed. Reply to "KEAP1-NFE2L2-Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis".
    J Thorac Oncol. 2020;15:e87-e88.
    PubMed    


  418. ZHANG C, Zhang C, Li J, Wang H, et al
    KEAP1-NFE2L2-Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis.
    J Thorac Oncol. 2020;15:e85-e86.
    PubMed    


  419. DAGOGO-JACK I, Lennerz JK
    Personalized Diagnostic Workflows: The Next Wave of Precision Medicine in NSCLC.
    J Thorac Oncol. 2020;15:888-890.
    PubMed    


  420. CARBONE M
    Transitional Mesothelioma and Artificial Intelligence: Do We Need One More Subtype? and Do We Need Computers to Identify Them?
    J Thorac Oncol. 2020;15:884-887.
    PubMed    


  421. NAGASAKA M, Ou SI
    Is NRG2alpha Fusion a "Doppelganger" to NRG1alpha/beta Fusions in Oncology?
    J Thorac Oncol. 2020;15:878-880.
    PubMed    


  422. ZHANG C, Yan LX, Jiang BY, Wu YL, et al
    Feasibility and Safety of Neoadjuvant Alectinib in a Patient With ALK-Positive Locally Advanced NSCLC.
    J Thorac Oncol. 2020;15:e95-e99.
    PubMed    


  423. CHURG A, Dacic S, Galateau-Salle F, Attanoos R, et al
    Malignant Mesothelioma In Situ: Clinical and Pathologic Implications.
    J Thorac Oncol. 2020;15:899-901.
    PubMed    


  424. ZHANG J, Zou C, Zhou C, Luo Y, et al
    A Novel Linc00308/D21S2088E Intergenic Region ALK Fusion and Its Enduring Clinical Responses to Crizotinib.
    J Thorac Oncol. 2020;15:1073-1077.
    PubMed    


  425. REMON J, Passiglia F, Ahn MJ, Barlesi F, et al
    Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations.
    J Thorac Oncol. 2020;15:914-947.
    PubMed     Abstract available


  426. GALATEAU SALLE F, Le Stang N, Tirode F, Courtiol P, et al
    Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center.
    J Thorac Oncol. 2020;15:1037-1053.
    PubMed     Abstract available


  427. DECESARIS CM, McCarroll R, Mishra MV, Glass E, et al
    Assessing Outcomes of Patients Treated With Re-Irradiation Utilizing Proton Pencil-Beam Scanning for Primary or Recurrent Malignancies of the Esophagus and Gastroesophageal Junction.
    J Thorac Oncol. 2020;15:1054-1064.
    PubMed     Abstract available


  428. GOODMAN CD, Nijman SFM, Senan S, Nossent EJ, et al
    A Primer on Interstitial Lung Disease and Thoracic Radiation.
    J Thorac Oncol. 2020;15:902-913.
    PubMed     Abstract available


  429. KOHSAKA S, Hayashi T, Nagano M, Ueno T, et al
    Identification of Novel CD74-NRG2alpha Fusion From Comprehensive Profiling of Lung Adenocarcinoma in Japanese Never or Light Smokers.
    J Thorac Oncol. 2020;15:948-961.
    PubMed     Abstract available


  430. ZHAO S, Fang W, Pan H, Yang Y, et al
    Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma.
    J Thorac Oncol. 2020;15:962-972.
    PubMed     Abstract available


  431. LOTSBERG ML, Wnuk-Lipinska K, Terry S, Tan TZ, et al
    AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells.
    J Thorac Oncol. 2020;15:973-999.
    PubMed     Abstract available


  432. SHI Y, Zhang S, Hu X, Feng J, et al
    Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation.
    J Thorac Oncol. 2020;15:1015-1026.
    PubMed     Abstract available


    May 2020
  433. BEST SA, Hess J, Souza-Fonseca-Guimaraes F, Cursons J, et al
    Harnessing natural killer immunity in metastatic small cell lung cancer.
    J Thorac Oncol. 2020 May 26. pii: S1556-0864(20)30394.
    PubMed     Abstract available


  434. OUYANG W, Hu J, Zhang H, Xie C, et al
    The Management of Patients With Lung Cancer During the Outbreak of Coronavirus Disease 2019.
    J Thorac Oncol. 2020 May 23. pii: S1556-0864(20)30385.
    PubMed    


  435. HEEKE S, Benzaquen J, Hofman V, Long-Mira E, et al
    Brief Report: Comparison of three sequencing panels used for the assessment of tumor mutational burden in non-small cell lung cancer demonstrates low comparability.
    J Thorac Oncol. 2020 May 22. pii: S1556-0864(20)30417.
    PubMed     Abstract available


  436. SMELTZER MP, Wynes MW, Lantuejoul S, Soo R, et al
    The International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung Cancer.
    J Thorac Oncol. 2020 May 14. pii: S1556-0864(20)30383.
    PubMed     Abstract available


  437. DINGEMANS AC, Soo RA, Jazieh AR, Rice SJ, et al
    Treatment guidance for lung cancer patients during the COVID-19 pandemic.
    J Thorac Oncol. 2020 May 13. pii: S1556-0864(20)30382.
    PubMed     Abstract available


  438. MANJUNATH Y, Mitchem JB, Suvilesh KN, Avella DM, et al
    Circulating giant tumor-macrophage fusion cells are independent prognosticators in non-small cell lung cancer patients.
    J Thorac Oncol. 2020 May 13. pii: S1556-0864(20)30381.
    PubMed     Abstract available


  439. AL-SAMKARI H, Leiva O, Dagogo-Jack I, Shaw A, et al
    Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2020 May 10. pii: S1556-0864(20)30380.
    PubMed     Abstract available


  440. HONG L, Negrao MV, Dibaj SS, Chen R, et al
    Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2020 May 7. pii: S1556-0864(20)30373.
    PubMed     Abstract available


  441. ZHU J, Zhang Y, Gao XH, Xi EP, et al
    COVID-19 or Lung Cancer: A differential diagnostic experience and management model from Wuhan.
    J Thorac Oncol. 2020 May 6. pii: S1556-0864(20)30377.
    PubMed    


  442. LEE JC, Blazak JK
    The Use of Positron Emission Tomography in Coronavirus Disease 2019 Cases.
    J Thorac Oncol. 2020 May 5. pii: S1556-0864(20)30374.
    PubMed    


  443. CHANG HL, Chen YH, Yang CJ
    Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)-Associated Interstitial Lung Disease During the COVID-19 Pandemic.
    J Thorac Oncol. 2020 May 5. pii: S1556-0864(20)30376.
    PubMed    


  444. DAI J, Sun L, Jin K, Jiang G, et al
    Identifiable and Unidentifiable Factors Influencing Lymph Node Examination and Adjuvant Chemotherapy in Stage I Lung Cancer.
    J Thorac Oncol. 2020;15:e78-e79.
    PubMed    


  445. TIAN S, Xiao SY
    Pathology of 2019 Novel Coronavirus Pneumonia: A Dynamic Disease Process.
    J Thorac Oncol. 2020;15:e67-e68.
    PubMed    


  446. BOGOS K, Kiss Z, Galffy G, Tamasi L, et al
    Lung Cancer in Hungary.
    J Thorac Oncol. 2020;15:692-699.
    PubMed    


  447. JOOB B, Wiwanitkit V
    Pulmonary Pathology of Early Phase 2019 Novel Coronavirus Pneumonia.
    J Thorac Oncol. 2020;15:e67.
    PubMed    


  448. WO Y, Wang Y, Lu T, Sun D, et al
    Evaluated Lymph Node Number in Population-Based Analyses: Significant Prognostic Factor, but Assess With Caution.
    J Thorac Oncol. 2020;15:e77-e78.
    PubMed    


  449. FRIEDBERG JS, Culligan MJ, Tsao AS, Rusch V, et al
    Reply to Waller et al. Standardizing Surgical Treatment for Mesothelioma.
    J Thorac Oncol. 2020;15:e75-e77.
    PubMed    


  450. WALLER DA, Bilancia R, Bille A, Tenconi S, et al
    Standardizing Surgical Treatment of Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2020;15:e73-e74.
    PubMed    


  451. WANG Z, Duan J, Wang J, Wang G, et al
    In Reply: A Modified Algorithm Adjusting Both High and Minor Allele-Frequency to Redefine Blood-Based Tumor Mutational Burden for Optimal Prediction of Clinical Benefits From Programmed Cell Death-Protein 1 Immunotherapy.
    J Thorac Oncol. 2020;15:e72-e73.
    PubMed    


  452. LIU Z, Xie Z, Cai X, He J, et al
    A Modified Algorithm Adjusting Both High and Minor Allele Frequency Mutation to Redefine Blood-Based Tumor Mutational Burden (bTMB) for Optimal Prediction of Clinical Benefits From Immune Checkpoint Inhibitor Therapy.
    J Thorac Oncol. 2020;15:e69-e72.
    PubMed    


  453. PEIKERT T
    Personalized Oncolytic Therapy: The Next Step Toward the Successful Clinical Application of Vaccine-Strain Measles Viruses for Cancer Therapy?
    J Thorac Oncol. 2020;15:689-691.
    PubMed    


  454. DE MIGUEL FJ
    An Elaborate STING Operation to Take Down NSCLC: Combination of Immunotherapies and Chemotherapies.
    J Thorac Oncol. 2020;15:686-688.
    PubMed    


  455. DENG L, Cheng H
    Uncommon as an Individual, Not That Uncommon as a Whole.
    J Thorac Oncol. 2020;15:681-685.
    PubMed    


  456. YASUDA H
    Targeting Co-Occurring Genomic Alterations in MET Exon 14 Skipping Mutation-Positive NSCLC.
    J Thorac Oncol. 2020;15:679-680.
    PubMed    


  457. CARBONE M, Green JB, Bucci EM, Lednicky JA, et al
    Coronaviruses: Facts, Myths, and Hypotheses.
    J Thorac Oncol. 2020;15:675-678.
    PubMed    


  458. WARREN GW, Alberg AJ, Cummings KM, Dresler C, et al
    Smoking Cessation After a Cancer Diagnosis Is Associated With Improved Survival.
    J Thorac Oncol. 2020;15:705-708.
    PubMed    


  459. JAMME P, Fernandes M, Copin MC, Descarpentries C, et al
    Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations.
    J Thorac Oncol. 2020;15:741-751.
    PubMed     Abstract available


  460. DELLA CORTE CM, Sen T, Gay CM, Ramkumar K, et al
    STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype.
    J Thorac Oncol. 2020;15:777-791.
    PubMed     Abstract available


  461. VAGHJIANI RG, Takahashi Y, Eguchi T, Lu S, et al
    Tumor Spread Through Air Spaces Is a Predictor of Occult Lymph Node Metastasis in Clinical Stage IA Lung Adenocarcinoma.
    J Thorac Oncol. 2020;15:792-802.
    PubMed     Abstract available


  462. RATHKEY D, Khanal M, Murai J, Zhang J, et al
    Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression.
    J Thorac Oncol. 2020;15:843-859.
    PubMed     Abstract available


  463. DOMBLIDES C, Leroy K, Monnet I, Mazieres J, et al
    Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma.
    J Thorac Oncol. 2020;15:860-866.
    PubMed     Abstract available


  464. DELAUNAY T, Achard C, Boisgerault N, Grard M, et al
    Frequent Homozygous Deletions of Type I Interferon Genes in Pleural Mesothelioma Confer Sensitivity to Oncolytic Measles Virus.
    J Thorac Oncol. 2020;15:827-842.
    PubMed     Abstract available


    April 2020
  465. KUMAR S, Chmura S, Robinson C, Lin SH, et al
    Alternative Multidisciplinary Management Options for Locally Advanced Non-Small Cell Lung Cancer During the COVID-19 Global Pandemic.
    J Thorac Oncol. 2020 Apr 28. pii: S1556-0864(20)30331.
    PubMed     Abstract available


  466. GROTE HJ, Feng Z, Schlichting M, Helwig C, et al
    PD-L1 Immunohistochemistry Assay Comparison Studies in Non-Small Cell Lung Cancer: Characterization of the 73-10 Assay.
    J Thorac Oncol. 2020 Apr 27. pii: S1556-0864(20)30327.
    PubMed     Abstract available


  467. SIMONS EA, Smith DE, Gao D, Camidge DR, et al
    Variation in toxicity reporting methods for early phase lung cancer treatment trials at oncology conferences.
    J Thorac Oncol. 2020 Apr 27. pii: S1556-0864(20)30335.
    PubMed     Abstract available


  468. CAFAROTTI S
    SARS-COV2 INFECTION AND LUNG CANCER PATIENTS: the potential role of IL17 target therapy.
    J Thorac Oncol. 2020 Apr 27. pii: S1556-0864(20)30330.
    PubMed     Abstract available


  469. SANZ-SANTOS J, Rami-Porta R, Call S
    Lessons already learnt from the Covid-19 pandemic.
    J Thorac Oncol. 2020 Apr 22. pii: S1556-0864(20)30326.
    PubMed    


  470. WARREN G, Adjei AA
    A CALL FOR RAPID SUBMISSION OF DATA FOR AGGREGATE REVIEW: Can daily radiotherapy imaging be used as a potential screen for COVID-19?
    J Thorac Oncol. 2020 Apr 21. pii: S1556-0864(20)30318.
    PubMed    


  471. OUYANG W, Yu J, Zhang J, Xie C, et al
    Alert to Potential Contagiousness: A Case of Lung Cancer with Asymptomatic SARS-CoV-2 Infection.
    J Thorac Oncol. 2020 Apr 16. pii: S1556-0864(20)30300.
    PubMed    


  472. TORLAKOVIC E, Albadine R, Bigras G, Boag A, et al
    Canadian Multicentre Project on Standardization of PD-L1 22C3 Immunohistochemistry Laboratory Developed Tests for Pembrolizumab Therapy in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2020 Apr 15. pii: S1556-0864(20)30293.
    PubMed     Abstract available


  473. CAFAROTTI S, Patella M
    LUNG CANCER SURGICAL MANAGEMENT DURING THE OUTBREAK OF COVID-19.
    J Thorac Oncol. 2020 Apr 11. pii: S1556-0864(20)30291.
    PubMed    


  474. SUZUKI Y, Karayama M, Uto T, Fujii M, et al
    Assessment of Immune-Related Interstitial Lung Disease in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: A Multi-Center Prospective Study.
    J Thorac Oncol. 2020 Apr 11. pii: S1556-0864(20)30297.
    PubMed     Abstract available


  475. CAI Y, Hao Z, Gao Y, Ping W, et al
    COVID-19 in the perioperative period of lung resection: a brief report from a single thoracic surgery department in Wuhan, China.
    J Thorac Oncol. 2020 Apr 11. pii: S1556-0864(20)30298.
    PubMed     Abstract available


  476. SUPPLI MH, Riisgaard de Blanck S, Elgaard T, Josipovic M, et al
    Early appearance of COVID-19 associated pulmonary infiltrates during daily radiotherapy imaging for lung cancer.
    J Thorac Oncol. 2020 Apr 10. pii: S1556-0864(20)30299.
    PubMed    


  477. RUSSANO M, Citarella F, Vincenzi B, Tonini G, et al
    COVID-19 or Lung Cancer: what should we treat?
    J Thorac Oncol. 2020 Apr 10. pii: S1556-0864(20)30294.
    PubMed    


  478. JOTTE R, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, et al
    Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous Non-Small-Cell Lung Cancer (IMpower131): Results From a Randomized Phase III Trial.
    J Thorac Oncol. 2020 Apr 7. pii: S1556-0864(20)30292.
    PubMed     Abstract available


  479. YANG H
    Co-Occurring LKB1 Deficiency Determinates the Susceptibility to ERK-Targeted Therapy in RAS-Mutant Lung Cancer.
    J Thorac Oncol. 2020;15:e58-59.
    PubMed    


  480. KAIRA K, Ogiwara Y, Naruse I
    Occurrence of Ventricular Fibrillation in a Patient With Lung Cancer Receiving Osimertinib.
    J Thorac Oncol. 2020;15:e54-e55.
    PubMed    


  481. GRINBERG RD, Refaely Y, Cohen LB, Shaham D, et al
    Lung Cancer in Israel.
    J Thorac Oncol. 2020;15:493-498.
    PubMed    


  482. TREMBLAY A
    Reply and Commentary to "Smoking Cessation Interventions in the Setting of Low-Dose Computed Tomography: Are They Effective?"
    J Thorac Oncol. 2020;15:e61-e62.
    PubMed    


  483. SANGUANKEO A
    Smoking Cessation Interventions in the Setting of Low-Dose Computed Tomography: Are They Effective?
    J Thorac Oncol. 2020;15:e60.
    PubMed    


  484. CAIOLA E, Broggini M, Marabese M
    LKB1ness Dictates ERK Inhibitors Response in NSCLC.
    J Thorac Oncol. 2020;15:e59.
    PubMed    


  485. EGUREN-SANTAMARIA I, Sanmamed MF, Gil-Bazo I
    Are Immune Checkpoint Inhibitors Effective Against Uncommon Oncogene-Driven NSCLC Subtypes?
    J Thorac Oncol. 2020;15:489-492.
    PubMed    


  486. ZHOU F, Zhou C
    Treatment Algorithm for Advanced ALK-Rearranged NSCLC: A Marathon Rather Than a Sprint.
    J Thorac Oncol. 2020;15:485-488.
    PubMed    


  487. SOLOMON B
    Identifying Mechanisms of Resistance to ALK Tyrosine Kinase Inhibitors Using Analysis of Circulating Tumor DNA.
    J Thorac Oncol. 2020;15:482-484.
    PubMed    


  488. XIA B, Ou SI
    Simultaneous RET Solvent-Front and Gatekeeper Resistance Mutations In Trans: A Rare TKI-Specific Therapeutic Challenge?
    J Thorac Oncol. 2020;15:479-481.
    PubMed    


  489. BU K, Lu Y, Liu X, Cheng C, et al
    Lysocardiolipin Acyltransferase 1-Anaplastic Lymphoma Receptor Tyrosine Kinase: A Novel Crizotinib-Sensitive Fusion Gene in Lung Adenocarcinoma.
    J Thorac Oncol. 2020;15:e55-e57.
    PubMed    


  490. LV Y, Ling F, Zhang J, Xiao M, et al
    A Novel Intergenic LSM14A-RET Fusion Variant in a Patient With Lung Adenocarcinoma.
    J Thorac Oncol. 2020;15:e52-e53.
    PubMed    


  491. XU J, Jiang Q, Xu H, Liu A, et al
    Two Patients Having NSCLC With Novel Duplication Mutation in Their EGFR Gene (p.I740_K745dupIPVAIK) and Their Response to Osimertinib.
    J Thorac Oncol. 2020;15:e49-e51.
    PubMed    


  492. SOLOMON BJ, Tan L, Lin JJ, Wong SQ, et al
    RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
    J Thorac Oncol. 2020;15:541-549.
    PubMed     Abstract available


  493. AHN MJ, Chiu CH, Cheng Y, Han JY, et al
    Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis.
    J Thorac Oncol. 2020;15:637-648.
    PubMed     Abstract available


  494. YAGI Y, Aly RG, Tabata K, Barlas A, et al
    Three-Dimensional Histologic, Immunohistochemical, and Multiplex Immunofluorescence Analyses of Dynamic Vessel Co-Option of Spread Through Air Spaces in Lung Adenocarcinoma.
    J Thorac Oncol. 2020;15:589-600.
    PubMed     Abstract available


  495. GUO R, DuBoff M, Jayakumaran G, Kris MG, et al
    Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas.
    J Thorac Oncol. 2020;15:655-660.
    PubMed     Abstract available


  496. KIM H, Goo JM, Kim YT, Park CM, et al
    Validation of the Eighth Edition Clinical T Categorization System for Clinical Stage IA, Resected Lung Adenocarcinomas: Prognostic Implications of the Ground-Glass Opacity Component.
    J Thorac Oncol. 2020;15:580-588.
    PubMed     Abstract available


  497. RODEN AC, Fang W, Shen Y, Carter BW, et al
    Distribution of Mediastinal Lesions Across Multi-Institutional, International, Radiology Databases.
    J Thorac Oncol. 2020;15:568-579.
    PubMed     Abstract available


  498. NOE J, Lovejoy A, Ou SI, Yaung SJ, et al
    ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials.
    J Thorac Oncol. 2020;15:601-608.
    PubMed     Abstract available


    March 2020
  499. POLVERARI G, Arena V, Ceci F, Pelosi E, et al
    (18)F-FDG uptake in Asymptomatic SARS-CoV-2 (COVID-19) patient, referred to PET/CT for Non-Small Cells Lung Cancer restaging.
    J Thorac Oncol. 2020 Mar 31. pii: S1556-0864(20)30286.
    PubMed    


  500. BONOMI L, Ghilardi L, Arnoldi E, Tondini CA, et al
    A rapid fatal evolution of Coronavirus Disease-19 (COVID-19) in an advanced lung cancer patient with a long time response to nivolumab.
    J Thorac Oncol. 2020 Mar 31. pii: S1556-0864(20)30285.
    PubMed    


  501. DE SOUZA GUTIERRES B, Aguiar PN Jr, Dourado BB, Alves AL, et al
    Evidence Strength of Pharmaceutical Industry Funded Clinical Trials in Metastatic Non-Small Cell Lung Cancer: A Comparison with Other Sources of Funding.
    J Thorac Oncol. 2020 Mar 23. pii: S1556-0864(20)30196.
    PubMed     Abstract available


  502. LI T
    Managing the Isolated Central Nervous System Progression in Patients With Oncogene-Driven Metastatic NSCLC: Does Circulating Tumor DNA Add to Management?
    J Thorac Oncol. 2020;15:314-316.
    PubMed    


  503. MACAYA I, Entrialgo-Cadierno R, Valencia K, Vicent S, et al
    Liver Kinase B1 (LKB1) Loss Has its p-ERKs: ERK Inactivation as a Vulnerability in NSCLC With LKB1 Mutations.
    J Thorac Oncol. 2020;15:311-313.
    PubMed    


  504. MENIS J, Reck M
    Checkpoint Inhibitors in SCLC: How Much Can We Trust in Randomized Cohorts of Phase I/II Trials?
    J Thorac Oncol. 2020;15:308-310.
    PubMed    


  505. DE-RUI HUANG D, Chih-Hsin Yang J
    Checkpoint Inhibitor Combined With Tyrosine Kinase Inhibitor-the End or Beginning?
    J Thorac Oncol. 2020;15:305-307.
    PubMed    


  506. ZHANG Q, Jiang T, Xiao M, Zhang J, et al
    Identification of a Novel Osimertinib-Sensitive Mutation, EGFR H773L, in a Chinese Patient With NSCLC.
    J Thorac Oncol. 2020;15:e46-e48.
    PubMed    


  507. WANG L, Yao S, Teng L, Zhang W, et al
    Melanoregulin-Anaplastic Lymphoma Kinase (ALK), a Novel ALK Rearrangement That Responds to Crizotinib in Lung Adenocarcinoma.
    J Thorac Oncol. 2020;15:e44-e46.
    PubMed    


  508. FUKUDO M, Sasaki T, Ohsaki Y
    PD-1 Blockers: Staying Long in the Body and Delayed Toxicity Risks.
    J Thorac Oncol. 2020;15:e42-e44.
    PubMed    


  509. KANEMURA H, Hayashi H, Hagiwara S, Otani T, et al
    Severe Immune-Related Hepatitis Treated With Plasma Exchange.
    J Thorac Oncol. 2020;15:e39-e42.
    PubMed    


  510. MAO W, Chen R, Zhang J, Zheng M, et al
    TMED2-ALK, a Novel ALK Fusion Gene Identified in a Patient With Lung Adenocarcinoma.
    J Thorac Oncol. 2020;15:e37-e39.
    PubMed    


  511. FANG W, Huang Y, Gan J, Zheng Q, et al
    Emergence of EGFR G724S After Progression on Osimertinib Responded to Afatinib Monotherapy.
    J Thorac Oncol. 2020;15:e36-e37.
    PubMed    


  512. FANG W, Huang Y, Gan J, He B, et al
    Nintedanib Effect in Osimertinib-Induced Interstitial Pneumonia.
    J Thorac Oncol. 2020;15:e34-e35.
    PubMed    


  513. OH S, Lim JH, Park N, Choi S, et al
    Dual Inhibition of EGFR and BRAF Can Be Harmful in Patients Harboring an EGFR-Activating Mutation.
    J Thorac Oncol. 2020;15:e32-e34.
    PubMed    


  514. WANG H, Tian R, Gao P, Wang Q, et al
    Tocilizumab for Fulminant Programmed Death 1 Inhibitor-Associated Myocarditis.
    J Thorac Oncol. 2020;15:e31-e32.
    PubMed    


  515. MOLINA-VILA MA, Stahel RA, Dafni U, Jordana-Ariza N, et al
    Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial.
    J Thorac Oncol. 2020;15:416-425.
    PubMed     Abstract available


  516. PELOSI G, Sabella G, Cannone M, Balladore E, et al
    Parietal Pleura-Based Malignant Perivascular Epithelioid Cell Neoplasm Protruding Into Serous Cavity: A Hitherto Unrecognized Occurrence.
    J Thorac Oncol. 2020;15:462-466.
    PubMed    


  517. OSAROGIAGBON RU, Faris NR, Stevens W, Fehnel C, et al
    Beyond Margin Status: Population-Based Validation of the Proposed International Association for the Study of Lung Cancer Residual Tumor Classification Recategorization.
    J Thorac Oncol. 2020;15:371-382.
    PubMed     Abstract available


  518. RUFFINI E, Fang W, Guerrera F, Huang J, et al
    The International Association for the Study of Lung Cancer Thymic Tumors Staging Project: The Impact of the Eighth Edition of the Union for International Cancer Control and American Joint Committee on Cancer TNM Stage Classification of Thymic Tumors.
    J Thorac Oncol. 2020;15:436-447.
    PubMed     Abstract available


  519. MIAN I, Abdullaev Z, Morrow B, Kaplan RN, et al
    Anaplastic Lymphoma Kinase Gene Rearrangement in Children and Young Adults With Mesothelioma.
    J Thorac Oncol. 2020;15:457-461.
    PubMed     Abstract available


  520. LIU H, Gu Z, Qiu B, Detterbeck FC, et al
    A Recurrence Predictive Model for Thymic Tumors and Its Implication for Postoperative Management: a Chinese Alliance for Research in Thymomas Database Study.
    J Thorac Oncol. 2020;15:448-456.
    PubMed     Abstract available


    February 2020
  521. SANDS JM, Milan MSD, Oxnard GR
    Blood-Based Disease Assessment in SCLC: A Perpetual Proof of Concept or a Clinically Important Tool?
    J Thorac Oncol. 2020;15:163-165.
    PubMed    


  522. JOHKOH T
    Take a Look at Clinical Data in Detail, Analyze Them, and Develop a New Diagnostic Method.
    J Thorac Oncol. 2020;15:158.
    PubMed    


  523. LE TALLEC E, Lescoat A, Ballerie A, Cador B, et al
    Eosinophilic Fasciitis Triggered by Nivolumab: A Remarkable Efficacy of the mTOR Inhibitor Sirolimus.
    J Thorac Oncol. 2020;15:e29-e30.
    PubMed    


  524. KABBASH MS, Edmund J, Ghafoor A, Hassan R, et al
    Intracardiac Involvement by Primary Malignant Mesothelioma: A Report of Two Cases.
    J Thorac Oncol. 2020;15:e25-e27.
    PubMed    


  525. LU R, Qi C, Xiao M, Cai S, et al
    STRN3-NTRK1: A Novel NTRK1 Oncogenic Fusion in a Patient with Lung Adenocarcinoma.
    J Thorac Oncol. 2020;15:e23-e24.
    PubMed    


  526. REKHTMAN N, Montecalvo J, Chang JC, Alex D, et al
    SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas.
    J Thorac Oncol. 2020;15:231-247.
    PubMed     Abstract available


  527. SUH YJ, Lee HJ, Sung P, Yoen H, et al
    A Novel Algorithm to Differentiate Between Multiple Primary Lung Cancers and Intrapulmonary Metastasis in Multiple Lung Cancers With Multiple Pulmonary Sites of Involvement.
    J Thorac Oncol. 2020;15:203-215.
    PubMed     Abstract available


  528. GRAY JE, Villegas A, Daniel D, Vicente D, et al
    Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC.
    J Thorac Oncol. 2020;15:288-293.
    PubMed     Abstract available


    January 2020
  529. DAVIES KD, Merrick DT
    Skipping Expected Mechanisms of MET-Mediated Oncogenesis.
    J Thorac Oncol. 2020;15:9-11.
    PubMed    


  530. SCHOENFELD AJ, Yu HA
    The Evolving Landscape of Resistance to Osimertinib.
    J Thorac Oncol. 2020;15:18-21.
    PubMed    


  531. NESTLE U, Adebahr S, van Herk M
    Retrospective Analyses of Registry Data for Technical Radiation Oncology Questions: Apples Versus Pears or Solid Evidence?
    J Thorac Oncol. 2020;15:15-17.
    PubMed    


  532. ARULANANDA S, John T
    Gefitinib and Pemetrexed Improve Survival in EGFR-Mutated NSCLC - Tarring all Patients With the Same Brush?
    J Thorac Oncol. 2020;15:12-14.
    PubMed    


  533. PENG Y, Zhang L, Zeng T, Liu L, et al
    Characterization of Hyperprogression After Immunotherapy in a Lung Adenocarcinoma Patient With Strong Expression of Programmed Death Ligand 1.
    J Thorac Oncol. 2020;15:e4-e8.
    PubMed    


  534. HIRANO S, Hayama N, Tabeta H, Kuroki T, et al
    Drastic Response of Rechallenge of Nivolumab in a Patient with NSCLC Who Progressed on the First Nivolumab Treatment.
    J Thorac Oncol. 2020;15:e20-e22.
    PubMed    


  535. VAN TURENHOUT ST, Berghuis M, Snaebjornsson P, Wilgenhof S, et al
    Cytomegalovirus in Steroid-Refractory Immune Checkpoint Inhibition-Related Colitis.
    J Thorac Oncol. 2020;15:e15-e20.
    PubMed    


  536. GAUTSCHI O, Menon R, Bertrand M, Murer C, et al
    Capmatinib and Osimertinib Combination Therapy for EGFR-Mutant Lung Adenocarcinoma.
    J Thorac Oncol. 2020;15:e13-e15.
    PubMed    


  537. WANG Z, Jia Q, Tang X, Yan L, et al
    Transformation to Lung Adenocarcinoma From Complete Remission-Experienced SCLC.
    J Thorac Oncol. 2020;15:e1-e3.
    PubMed    


  538. SCAGLIOTTI G, Moro-Sibilot D, Kollmeier J, Favaretto A, et al
    A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients.
    J Thorac Oncol. 2020;15:80-90.
    PubMed     Abstract available


  539. BALDACCI S, Figeac M, Antoine M, Descarpentries C, et al
    High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study.
    J Thorac Oncol. 2020;15:120-124.
    PubMed     Abstract available


  540. MIKUBO M, Seto K, Kitamura A, Nakaguro M, et al
    Calculating the Tumor Nuclei Content for Comprehensive Cancer Panel Testing.
    J Thorac Oncol. 2020;15:130-137.
    PubMed     Abstract available


  541. TAN VS, Correa RJM, Rodrigues GB, Palma DA, et al
    Intraluminal Superior Vena Cava Invasion.
    J Thorac Oncol. 2020;15:144-145.
    PubMed    


  542. SCHENK EL, Mandrekar SJ, Dy GK, Aubry MC, et al
    A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer
    J Thorac Oncol. 2020;15:110-119.
    PubMed     Abstract available


  543. NICHOLSON AG, Sauter JL, Nowak AK, Kindler HL, et al
    EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach.
    J Thorac Oncol. 2020;15:29-49.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: